



Review

Tissue-Specific Decellularization Methods: Rationale and Strategies to Achieve Regenerative Compounds

Unai Mendibil ^{1,2}, Raquel Ruiz-Hernandez ^{1,†} , Sgoi Retegi-Carrion ^{1,†} ,
Nerea Garcia-Urquia ^{2,†}, Beatriz Olalde-Graells ² and Ander Abarrategi ^{1,3,*}

¹ Center for Cooperative Research in Biomaterials (CIC biomaGUNE), Basque Research and Technology Alliance (BRTA), 20014 Donostia-San Sebastian, Spain; umendibil@cicbiomagune.es (U.M.); rruiz@cicbiomagune.es (R.R.-H.); sretegi@cicbiomagune.es (S.R.-C.)

² TECNALIA, Basque Research and Technology Alliance (BRTA), 20009 Donostia-San Sebastian, Spain; nerea.garcia@tecnalia.com (N.G.-U.); beatriz.olalde@tecnalia.com (B.O.-G.)

³ Ikerbasque, Basque Foundation for Science, 48013 Bilbao, Spain

* Correspondence: aabarrategi@cicbiomagune.es

† These authors contribute equally to the work.

Received: 15 July 2020; Accepted: 28 July 2020; Published: 30 July 2020



Abstract: The extracellular matrix (ECM) is a complex network with multiple functions, including specific functions during tissue regeneration. Precisely, the properties of the ECM have been thoroughly used in tissue engineering and regenerative medicine research, aiming to restore the function of damaged or dysfunctional tissues. Tissue decellularization is gaining momentum as a technique to obtain potentially implantable decellularized extracellular matrix (dECM) with well-preserved key components. Interestingly, the tissue-specific dECM is becoming a feasible option to carry out regenerative medicine research, with multiple advantages compared to other approaches. This review provides an overview of the most common methods used to obtain the dECM and summarizes the strategies adopted to decellularize specific tissues, aiming to provide a helpful guide for future research development.

Keywords: extracellular matrix; decellularization; regenerative medicine

1. Introduction

In many adult animal tissues, the main component in terms of volume is not the cells, but the cell-secreted three-dimensional (3D) structure known as the extracellular matrix (ECM). Structural and specialized proteins and proteoglycans are some of the ECM's macromolecular components, and they interact in this network with multiple key roles and functions. During homeostasis, the ECM provides structural integrity and mechanical support for tissues and organ architecture. In parallel, the ECM is the reservoir and the place for the active exchange of ions, nutrients, waters, metabolites, and signals [1]. In this way, the ECM serves as the environment in which tissue-resident cells attach, communicate, and interact, thereby regulating cell dynamics and behavior, and contributing to the maintenance of tissue-specific cell phenotypes and functions (Figure 1). Notably, the ECM provides a niche for tissue-resident stem cells and drives their fate decisions, a property particularly relevant during homeostasis and tissue repair–regeneration processes.




Figure 1. Structure, components, and functions of extracellular matrix (ECM) (MMP, matrix metalloprotease; GF, growth factor).

The properties of the ECM have been thoroughly used in tissue engineering and regenerative medicine research, aiming to restore the function of damaged or dysfunctional tissues [2]. In this context, applications of ECM-derived components are multiple, from *in vitro* stem cell basic research to clinical settings. For example, ECM-derived components have been used as surface coatings for cell adhesion purposes; gel matrices for establishing organoid cultures; 3D environments for cell seeding and growth factor delivery approaches; and as biocompatible and biomimetic implantable allograft or xenograft scaffolds with *in vivo* tissue regeneration properties. Often, strategies are based on specific ECM components, such as collagens, fibrin, hyaluronic acid, or even cell-culture-derived ECM. Using these materials, multiple fabrication techniques have been implemented to generate successful ECM-derived biomimetic structures such as hydrogels, or even more sophisticated engineering approaches such as micropatterned surfaces, electrospinning, 3D printing, and bioprinting-designed scaffolds, among others [3].

Interestingly, tissue decellularization is becoming a common technique to obtain decellularized extracellular matrix (dECM) [4] and it is a research field gaining momentum in recent years (Figure 2). The rationale for decellularization is related to the adverse response that cell waste may induce when tissue-derived material is used for implantation procedures, including immune reaction and inflammation, leading to implant rejection. Therefore, dECM is usually obtained by chemical, enzymatic, and/or physical decellularization methods, developed to eliminate the cells and their waste, mainly DNA [5]. These procedures yield decellularized materials formed by the multiple ECM components, which are maintained similar to the original tissue in composition, even in architecture, if required. dECM-related advantages are often associated with better performance and applicability as implants for tissue repair, and also with better mechanical/biochemical properties for the intended use. Initially, research in this field was focused precisely on developing proper decellularization methods and techniques, while more recently, the field is moving to implement approaches related to bioengineering and which tackle applied research aims.




Figure 2. Research items per year with the words “decellularization” or “decellularized” in the title (Source: <https://scholar.google.es> “allintitle: decellularized OR decellularization”).

Notably, regenerative medicine research can now take advantage of approaches based on the use of the targeted tissue-specific dECM [6,7]. The ECM is different from one tissue to another, and therefore, decellularization methods and techniques to obtain dECM have been extensively studied and tissue-specifically improved, aiming to preserve the ECM molecules and structures relevant for the intended use. In this sense, research has been mainly based on empirical testing of tissue-specific decellularization methods intended to achieve specific aims or applications.

In this review, we provide an overview of the methods used to obtain the dECM, and we summarize the most common strategies adopted to decellularize specific tissues, aiming to provide a helpful guide for future research development.

2. Organ Decellularization and Tissue Decellularization Approaches for Biomedical Applications

Whole tissue or intact tissue pieces or sections are a common starting point for decellularization, especially when the final purpose is whole organ decellularization for bioengineering purposes. In these cases, the resulting dECM is a tissue scaffold generally created to keep its structure as intact as possible. Note that dECM tissue scaffold decellularization processes tend to be long, due to the need to be sure about all the reagents reaching the target cells in order to achieve complete decellularization [5]. The bigger the tissue pieces, the longer it takes to make sure that they are completely decellularized. Moreover, the longer the period of chemicals and enzymatic reactions, the higher the chance of damaging the ECM components.

In tissue pieces, it is easy to assess by histology the decellularization and integrity of the remaining ECM. However, even if there are no histologically visible nuclei in the tissue, it is still important to quantify the DNA content by molecular techniques, with the safe limit of DNA content in a decellularized tissue established as below 50 pg DNA per milligram of dry tissue. Regarding macromolecules, they need to be assessed both in quantity and quality by histology, spectrophotometry, and other techniques, while the other ECM components as growth factors may need to be assessed and quantified as well [8]. In some cases, tissue-specific tests are also required to characterize those properties key to the intended biomedical application. For example, a mechanical stress test is required to assess the mechanical/elastic properties after the decellularization of tendons, muscles, and cartilage tissues [9].

Keeping the ECM as intact as possible can be a problem when dECM tissue scaffolds are meant to be used for cell colonization purposes [10]. The ECM is grown by and around the cells, providing physical support, and therefore keeping intact the intricate ECM net, which may impede proper cell seeding of decellularized material. Moreover, potential implantation may be physically limited by the dECM structure and form. Therefore, the decellularization strategy is often designed to degrade some of the ECM components, aiming to maximize the further cell seeding strategy [11].

Tissue decellularization is achieved using as starting material tissues treated with mechanical or chemical methods for tissue grinding, pulverization, or homogenization before decellularization.

This approach is gaining relevance, especially in strategies aiming to use the dECM in postprocessing fabrication approaches (hydrogels, 3D printing, electrospinning, and similar). The outcome of decellularization in these cases is dECM powder, an intermediate product mainly used to artificially generate further ECM coatings or 3D structures [12]. Note that tissue powder processing yields dECM powder with multiple components, but does not keep the tissue architecture and affects the structure of the ECM macromolecules. This is because the aim of approaches using this processing method is not to keep the structural proteins untouched, but rather to use the properties of the relevant ECM components to improve biocompatibility, adhesion, differentiation, and/or other properties or purposes.

The applications of decellularized materials and matrices in regenerative medicine context are multiple, including clinically used implantable materials, and continue to expand. For example, whole decellularized pieces are mainly used as scaffolds for transplantation purposes; dECM processed to form sheets and/or patches is useful in soft tissue and cardiac repair; Powder of demineralized bone matrix can be resuspended and be used to fill and heal bone defects; dECM-derived hydrogels are useful as injectable materials with regenerative properties; Hydrogels can be processed too, to generate inks and bioinks useful in 3D printing and electrospun-based strategies; dECM-derived scaffolds can be used as cell carriers for in vitro modeling or in vivo regenerative purposes [2,13–19].

In any case, the decellularization procedure selected and the further characterization needs depend on the final aim and approach (Figure 3). Whole organ, tissue pieces, or powdered ECM are the most common starting materials and multiple possible decellularization methods can be applied, all of them with advantages and disadvantages to be taken into account in light of the specific aim and context [18].




Figure 3. Schematic of organ decellularization and tissue decellularization approaches.

3. ECM Decellularization and Sterilization Methods

Most protocols describe combinatorial and sequential use of different physical, chemical, and enzymatic techniques in order to achieve tissue-specific decellularization. In general, chemical and enzymatic techniques are mainly responsible for successful decellularization in most protocols. Physical techniques are generally used to complement chemical and enzymatic techniques and therefore increase the decellularization effects (Table 1). Physical techniques can produce damage in the matrix, while chemical techniques can produce reactions that change the chemical composition of the ECM [20–22]. For this reason, setting up the decellularization protocol is of paramount importance in each specific approach.

3.1. Chemical and Enzymatic Methods for Decellularization

Detergents are chemical agents used to solubilize cell membranes and to dissociate their inner structure. Among them, Triton X-100 is the most commonly used detergent in decellularization processes. It targets the lipid–lipid and lipid–protein interactions, but it leaves the protein–protein interaction intact [9,23]. It is a very useful agent in those tissues where the key matrix components are primarily proteins. It is an effective detergent to eliminate cells from many tissues, but it is generally avoided in tissues with glycosaminoglycans (GAGs) as a key component in their matrix.

Side by side with the Triton X-100, sodium dodecyl sulfate (SDS) is the other most commonly used detergent in decellularization procedures. SDS solubilizes both the external and nuclear membranes, but also tends to denature proteins and may alter the native structure of the matrix [24,25]. For these reasons, short time SDS treatment is the most common, aiming to minimize the possible damage to proteins and the overall matrix structure [26]. Nevertheless, it is very efficient in removing nuclear and cytoplasmic waste.

Other detergents are useful for specific tissues and applications in a decellularization context. CHAPS reagent has properties of both ionic and nonionic detergents, and therefore, it targets lipid–lipid and lipid–protein interactions, while also solubilizes membranes [27]. CHAPS is not good as a permeating agent, and is therefore mainly used to decellularize thin tissues, for which it is more effective. Triton X-200 is another detergent, less used than its X-100 counterpart because it is more prone to alter the ECM's structure, but it is highly effective for tissues such as neural tissue [28].

Enzymes are also used in most decellularization protocols, mainly to eliminate cell waste and other undesirable components of the ECM. However enzymatic treatments can often lead to additional problems related to enzyme removal [20], a problem usually tackled with further steps using nonenzymatic agents or detergent treatment. Among such enzymes, trypsin is the most commonly used in decellularization procedures [29]. Trypsin targets the C-side bonds in arginine and lysine amino acids and is mostly used combined with EDTA, a chemical agent able to break cell–matrix interactions. Of note, the prolonged exposure to trypsin–EDTA treatment can significantly alter the structure of the matrix, destroy laminin, and remove GAGs, resulting in severe mechanical weakness of the tissue [30]. Pepsin is another useful enzyme in decellularization processes. It is a highly aggressive protease commonly found in the stomach and, like trypsin, it targets the bounds between peptides. Thus, it may cause damage to the ECM if used under long exposition times [31].

Hypotonic and hypertonic solutions [32] use osmotic properties to make the cells explode. The osmotic shock kills the cells, but it does not remove the cell waste that it releases to the matrix, which should be taken into account in the design of a decellularization procedure. Moreover, the treatment of the DNA waste is of paramount relevance in all decellularization processes, due to the tendency of the nuclear material to remain stuck to ECM proteins. In this sense, endonucleases and exonucleases are other kinds of enzymes that are of great use to eliminate the waste of nuclear components [8,30].

Finally, chemical acid–base [33] and TBP [32] treatments are rarely used, because they are very aggressive toward the proteins of the matrix. Specifically, acid–base solutions damage collagen and TBP disrupts protein–protein bonds.

3.2. Physical Methods for Decellularization

As previously mentioned, physical techniques are not enough to decellularize the tissue, but they can help in combination with chemical and enzymatic processes. For example, when big tissue pieces or whole organs are the target of decellularization, perfusion is recommended in order to better reach all tissue areas [21,34].

Table 1. Methods used in decellularization processes.

Methods	Mechanism	Side Effects on the ECM	References
Chemical			
Acid; Base	Solubilizes cytoplasmic components, disrupts nucleic acids	Damages collagen and GAG	[32]
Triton X-100	Breaks lipid–lipid and lipid–protein unions, while leaving the protein interactions untouched	Not recommended for ECM where the lipids and GAG are important components	[9,23,26,44,45]
SDS	Liquefies the internal and external cell membranes	Tends to denaturalize proteins and may induce nuclear and cytoplasmic waste in the remaining matrix	[24–26,46–48]
Triton X-200	Similar to its X-100 counterpart. Very effective in some tissues	Needs to be combined with a zwitterionic detergent to be effective. Damages the matrix in a similar way that SDS does.	[28]
CHAPS	Properties of ionic and nonionic detergents	Similar damage level compared to Triton X-100	[27]
TBP	Disrupts protein–protein interactions	Variable results, collagen degradation but keeping the mechanical properties	[25,49]
Hypertonic and hypotonic solutions	Osmotic pressure to make the membrane explode	High amount of cell waste in the remaining matrix	[11,33,50]
Enzymes			
EDTA, EGTA	Breaks cell adhesion to matrix. It is usually combined with trypsin	Does not actually kill the cells	[29,30,46,50,51]
Trypsin	Digestion of membrane proteins leading to cell dead	Can damage the proteins in the ECM, in particular laminin and GAG	[29,30,43,52]
Pepsin	It targets peptide bounds	Causes high damage in the ECM proteins if left for too long	[31]
Endonucleases and Exonucleases	Degradation of the nuclear material inside and outside of the nucleus	Further cleaning and enzyme removal is required, as they may promote immune response	[6,29,53–57]
Physical			
Freezing	Crystals created in the freezing process destroy the cell membrane	The overall protein structure of the ECM may be compromised	[24,35–38,58]
Force	Mechanical pressure can be enough to induce the lysis in some tissues	Limited to tissues with hard structures, as it can greatly damage the ECM structure	[39]
Agitation	Commonly used to facilitate chemical agent infiltration and to induce cell lysis	Aggressive processes like sonication can greatly damage the ECM	[40,41]
Vacuum-assisted decellularization (VAD)	Enables chemical agents to reach the more inner parts of the tissue	It is not a decellularization method but a facilitator	[42]
Hydrostatic pressure	Applies high pressure to the tissue and induces cell lysis	Excessive pressure can damage the structure	[43,59]

The most commonly used physical technique is snap freezing, or freeze–thawing, as the first step of a decellularization process. By freezing tissue, intracellular ice crystals are formed, thereby disrupting cellular membranes and causing cell lysis. Thus, freezing is a common and effective method for cell lysis and it eases further uniform decellularization. Protocols using this approach have to

carefully control the rate of temperature change to control the size of the formed ice crystals, therefore preventing excessive damage to the ECM [35–38].

Cells can be lysed by applying direct pressure to tissue, but this method is only effective for tissues or organs that are not characterized by a densely organized ECM (e.g., liver and lung). Mechanical force has also been used to delaminate layers of tissue from organs that are characterized by natural planes of dissection, such as the small intestine and the urinary bladder. These methods are effective and cause minimal disruption to the three-dimensional architecture of the ECM within these tissues [39].

Mechanical agitation and sonication are useful in combination with a chemical treatment to assist in cell lysis and the removal of cellular debris [40,41]. Mechanical agitation can be applied by using a magnetic stir plate, an orbital shaker, or a low-profile roller. There are no studies to determine the optimal magnitude or frequency of sonication for the disruption of cells. However, the standard ultrasonic cleaner appears to be as effective at removing cellular material as the movement of an orbital shaker. In all of these procedures, the optimal speed, the volume of reagent, and the length of mechanical agitation are dependent on the composition, volume, and density of the tissue.

Vacuum-assisted decellularization (VAD) cannot decellularize, but it is highly effective in enabling chemical agents to reach the whole tissue [42]. Hydrostatic pressure, on the other hand, is an effective decellularization method, but it is usually combined with enzymes such as DNases to achieve complete decellularization [43].

3.3. Sterilization Methods

The dECM is commonly used in *in vivo* implantable approaches. Therefore, in order to prevent the transmission of pathogens, the dECM needs to be sterilized to eliminate any microorganisms and to prevent infections [60]. There are some useful physical and chemical dECM sterilization techniques, although their suitability depends on multiple factors, which may need to be considered in each specific approach; for example, humidity, time of exposure, temperature, and the nature/load of the bioburden are some of the factors to be taken into account.

Among the physical methods, two groups are differentiated—those using heat and those using radiation. Heat techniques have very limited use in a dECM context, as dECM products are usually thermosensitive and high temperatures may denaturalize important proteins, as well as disrupt the structure [61,62]. Irradiation effectively eliminates microorganisms, and UV-irradiation is a common sterilization method used in research settings, mainly due to easy accessibility in terms of research labs and cell culture facilities [63]. On the other hand, gamma-irradiation is the preferred sterilization method for many pharmaceutical and clinical products, due to its high penetration, good assurance of sterilization, and feasible temperature during the sterilization process. Conversely, radiation may affect structural proteins such as collagen, reducing the strength of the treated material [64–66]. Therefore, gamma-irradiation is often selected as the sterilization method for dECM products, but the irradiation dosage has to be optimized for each specific case, and the properties must be assessed after treatment.

Liquid chemical wash can be used as a sterilization method. Alcohol-based sterilization is common in laboratories, as it is cheap and easy to access. This method is more effective at killing microbes in aqueous solutions, but may also affect the protein structure in dECM pieces. Phenols act by disrupting membranes, precipitating proteins, and inactivating enzymes. They are bactericidal, fungicidal, and mycobactericidal, but are ineffective against spores and most viruses. Aldehydes are alkylating agents that damage nucleic acids and kill all microorganisms, including spores. In contrast to alcohols, which are volatile, phenols and aldehydes are generally toxic, corrosive, and/or irritating. Liquid chemicals must be removed after the sterilization process due to their potential toxicity in further *in vivo* uses [60].

Chemical methods are also useful to sterilize dECM materials, and are an alternative to physical methods. Ozone and hydrogen peroxide are traditional sterilization gases, but ethylene oxide is more commonly used in a dECM context, as the ultrastructure and the mechanical properties of the dECM are usually not altered under such treatment [64,67]. After the sterilization process, it is important to ensure the elimination of residual sterilizing agents and other possible volatile residues.

4. Decellularization Methods by Tissue

In order to choose a decellularization method, the tissue itself and the strategy to be followed have to be taken into consideration. Since each tissue has a different structure and composition, the decellularization methods have to be specifically selected and empirically tested. Moreover, if the aim is to keep the tissue structure as intact as possible, chemical methods have to be chosen carefully because of the damage that they may cause to the structural macromolecules of the matrix. Therefore, the literature shows trends in the use of specific combinatorial physical and chemical approaches for each specific tissue and application, as follows.

4.1. Bone Tissue

Bones are the main components of the skeletal system. They give support to the body, allow movement, and produce red and white cells in their marrow. Bone is a connective tissue and its ECM is formed by different key proteins that confer tensile strength, such as collagen type I, noncollagenous glycoproteins, and proteoglycans. Calcium hydroxyapatite (HA) in the ECM serves to store minerals and provides specific properties to bone tissue, such as resistance and hardness [68], while a series of signaling molecules, such as bone morphogenetic proteins (BMPs), are also part of a bone's ECM compartment.

The properties of bone's ECM as regenerative material have been thoroughly described in the literature, and that is why diseased and damaged bones are frequently approached using bone grafts. Bone autografts are the best option in order to avoid rejection, while allografts and xenografts are often used [46,69–72]. Implantable ceramic scaffolds are also frequent in clinical settings as osteoconductive materials, and some of these products are bovine or porcine bone HA calcareous matrices obtained after heat-treating bones in a muffle furnace to remove all organic compounds, including cells [68,73].

The first use of decalcified bone as bone implantable material was described as early as 1889 by Senn [74], when he used muriatic acid as a decalcification agent, followed by washing and alcohol sterilization before implantation in human bone defects. However, the experimental evidence of the demineralized bone matrix (DBM) as an osteoinductive material was established by Urist in 1965 [52]. At present, osteoinductive activity in the bone matrix is largely related to some of the BMPs present in bone's ECM, and therefore, it is known that demineralization processing has to be done with the aim to preserve BMPs' biological activity. In any case, the DBM obtained by different decalcification methods is commercially available and extensively reported in clinical settings as an osteoinductive implantable material suitable for treating bone defects [70,75,76]. Hydrochloric acid (HCl) and EDTA are common decalcifying agents, while chloroform and methanol can be used for lipid extraction. Then, the DBM can be snap frozen, lyophilized, or kept at $-20\text{ }^{\circ}\text{C}$ until necessary [71,77].

The decellularized bone matrix (DecBM) is frequently achieved by chemical methods, such as EDTA in combination with trypsin or SDS, along with ammonium hydroxide [46,70]. Alternatively, thermal shock can be used, together with Triton X-100, for effective osseous tissue decellularization [44]. Additionally, high-hydrostatic pressurization, a physical method, has been used with good results regarding bone decellularization [60]. Nucleases and dehydrated alcohol are used as complementary and final steps in order to remove waste nuclear acids and other cellular remains [53,54].

Some authors have described specifically the serial decalcification and decellularization steps in their protocols toward the generation of cell-free demineralized implantable materials [71]. In this sense, hydrogels made from the ECM of decalcified and decellularized bone are quite common due to its versatility and osteoconductivity [53,70].

4.2. Cartilage Tissue

Cartilage in adult animals is a connective, smooth, and resilient tissue. Hyaline cartilage is avascular, and it is present in the stress points of skeletal tissue, such as bone heads, where it provides flexibility and prevents abrasion and damage [77]. It is also present in the rib cage, nose,

larynx, and trachea, while its extracellular matrix is composed of collagens, mainly collagen type II, glycosaminoglycans (GAGs), and laminin [78]. GAGs are closely related to cartilage mechanical properties and help the tissue to cope with sudden external forces [24]. Elastic cartilage is a supportive structure for tissues such as the outer ear and epiglottis, and histologically, it is similar to hyaline cartilage, but with much more elastic fibers [21]. On the other hand, fibrocartilage is the only cartilage with collagen type I in its structure, because it is a mixture of fibrous tissue and cartilaginous tissue, with unique toughness and elasticity properties, and is present in intervertebral discs and menisci, among others.

Hyaline cartilage is the most commonly targeted cartilage in regenerative treatment—in particular, the one covering the end of bones in articulations. Damage to articular cartilage is usually related to trauma or pathology, and can cause pain, osteoarthritis, or even loss of functionality [78]. Surgical interventions attempt to solve these conditions, but at present, they are largely temporary solutions, pushing research toward searching for new regenerative approaches. The lack of vascularization greatly limits the number of nutrients and oxygen that can reach the inner parts of the tissue. This condition makes cartilage regrowth particularly challenging [79]. Therefore, tackling articular cartilage regeneration is a challenging goal. The literature is extensive in terms of approaches aiming to regenerate articular cartilage tissue, using different kinds of implantable scaffolds [80,81]. In this sense, cartilage dECM derivatives have been used for coating other implantable materials or as a 3D-printed structure for knee and meniscal regeneration, among others.

The basics for articular cartilage decellularization are the same for the different types of cartilages, and in general, decellularization aims to keep in the matrix as many GAGs as possible. Of note, as the different cartilages have different permeability properties, it is paramount to set up proper conditions for optimum decellularization in each case.

Tissue snap freezing or freeze–thawing is a common pretreatment in many decellularization protocols [24,58]. Similarly, pretreatment with hypotonic and hypertonic solutions is also a popular method, used to induce apoptosis by osmotic pressure [11]. These methods do not decellularize the structure by itself, but they help further decellularization methods to work better and to reach the inner parts of the tissue. It has been proved that snap freezing does not affect the matrix component, and it has no significant negative impact on the structure [82]. Conversely, initial tissue homogenization, suggested in some articles, leads to the significant loss of GAGs and structural proteins [83].

Further to physical pretreatments, decellularization has been assayed with enzymatic or chemical detergent methods. The enzyme trypsin–EDTA is the most common decellularization approach reported [83]. Trypsin–EDTA breaks both the proteins that hold the cell in place inside the matrix, as well as the cell membrane proteins. Based on protease activity, the main setback of using this technique is the degradation of the proteins of potential interest in the final dECM. In order to prevent this, the exposure time to trypsin–EDTA needs to be highly controlled, and it is usually limited to 6–24 h [51].

Regarding the detergents used as decellularization reagents, Triton X-100 and SDS are the most commonly used ones. Both cause some extent of damage to the structure of the matrix, but the mechanical integrity of the matrix maintains at an acceptable level. Note that both incur damage to GAG content and integrity, being Triton X-100 the worse in this sense [26,45].

An additional issue to be taken into account regarding cartilage tissue is the need for enzymatic treatment with nuclease activity to prevent waste nucleic acid material from sticking to the matrix [11]. In elastic cartilage, the nuclease time may be necessarily longer to ensure decellularization. In articular cartilage, on the other hand, being a less dense structure, the risk of having DNA material stick to the protein matrix is lower.

The digestion of GAGs using chondroitinase ABC (ChABC) has been reported as a cartilage decellularization method. It is not a commonly used technique; although it facilitates the removal of native chondrocytes, it reduces the mechanical properties of the tissue as well [11].

4.3. Adipose Tissue

White adipose tissue is defined as a connective tissue that stores energy in the form of lipids (triglycerides), insulates the body, and provides cushioning and support for subcutaneous tissues and internal organs. It is composed of clusters of fat-storing cells (adipocytes) surrounded by a reticular fiber network and interspersed small blood vessels. The key ECM proteins of adipose tissue are collagen type I, collagen type IV, and laminin. Collagen with laminin provides anchoring sites and barrier functions for adipocytes. Collagen types IV and VII and laminin are major components of the basement membrane [84].

Reconstruction of soft tissue defects is needed after certain tumor resections, external injury, or due to congenital malformations, and presents a major challenge in plastic and reconstructive surgery. At present, the main complications related to adipose tissue reconstruction include capsular contracture, necrosis and donor site morbidity, and immune rejection, and therefore, new clinical approaches are required to improve the success rate. The subcutaneous adipose tissue discarded from surgical operations represents an abundant and easy-to-collect human tissue source, processable by dECM biomaterial [85]. In this sense, allograft and xenograft dECM biomimetic scaffolds have proved to be effective tools for promoting tissue repair and regeneration in numerous preclinical and clinical studies [86–88].

The optimal adipose tissue decellularization includes the extraction of lipids (delipidation), followed by the extraction of cells and cell components, thereby maintaining key proteins and the 3D structure. Human and porcine are the most common sources of adipose tissue extraction, and there are two different kinds of initial adipose tissue samples useful for decellularization purposes. Such samples can be solid tissue derived from resection surgery, usually performed in the abdominal area, which has to be cut into small pieces for decellularization. On the other hand, liposuction-derived samples are gel-like tissues that require homogenization and centrifugation as the initial step for separation of the lipid phase. After initial processing, decellularization can be achieved using detergent-based or detergent-free protocols [89].

A detergent-free method for adipose tissue decellularization was described by Flynn et al. in 2010, in which the dECM was produced with a combination of multiple physical and chemical strategies, such as freeze–thaw cycles in hypotonic buffer to loosen the ECM, isopropanol to remove lipids, and enzymatic digestion with trypsin–EDTA, DNase, RNase, and lipase to remove cells and lipids. The resulting dECM conserves the collagen architecture and provides a microenvironment for the differentiation of human adipose stem cells [90,91]. A further published similar protocol demonstrated, by immunohistochemical staining, that laminin and collagen type IV remain abundant in the decellularized matrix. *In vitro* and *in vivo* models with microporous foams and hydrogel scaffolds with cells both demonstrate strong support for adipogenesis and induce an angiogenic response and formation of new adipose tissue [55,92]. dECM scaffolds generated by similar detergent-free methods, with a combination of isopropanol, trypsin, EDTA, and DNase–RNase in gel-like liposuction-derived samples, served as support for human adipose-derived stem cells and adipose regeneration [93].

In adipose tissue, the use of detergents for decellularization seems to increase the risk of matrix protein denaturalization and degradation. Wang et al. reported a method with multiple sequential physical and chemical steps, including a polar solvent extraction and Triton X-100 treatment, which resulted in the maintenance of collagens but the absence of laminin in the final dECM [94]. Similar results were obtained when SDS was used during the decellularization process [95]. Note that although laminin was absent in Triton-X-100-treated samples, *in vivo* studies have confirmed that the dECM undergoes vascularization and adipose tissue regeneration at Day 30 of implantation, which is consistent with other reports on the adipose tissue-derived matrix.

4.4. Skeletal Muscle and Tendons

Muscles are connective tissues formed by contractile fibers. Skeletal muscles are responsible for voluntary movement and homeostasis, and they are attached to bones by collagen fibrillar structures

called tendons. Skeletal muscle is divided into several innervated and vascularized subtypes. Given the complex structure of skeletal muscle, it is difficult to pinpoint the exact distribution and composition of the ECM. Collagen is the most common component, as it contains collagen types I, II, III, IV, V, VI, XI, XII, XIV, XV, and XVIII. GAGs are ubiquitous in the ECM, while interactions between proteins and glycans are particularly important to regulate protein distribution. Moreover, ECM glycoproteins and cell membrane–protein interactions transmit the mechanical force in the muscle and are active during muscle injury regeneration [96].

Skeletal muscle loss is often the result of a traumatic injury. In this sense, reconstruction surgery may be required to recover functionality [97]. The first option is always an autologous transfer from nearby tissue, but this implicates a partial loss of functionality or volume. Among other approaches, the use of the muscle's decellularized ECM is a promising treatment, due to several reasons. Decellularized muscle xenografts are feasible, as a muscle's ECM is similar among different species, thereby minimizing the risk of the immune response [98,99]. Moreover, the dECM from skeletal muscle shows good integration *in vivo*, promoting vascularization, remodeling, and differentiation.

The initial skeletal muscle decellularization protocols included physical methods such as freeze–thawing or proteases, which have been further proven too aggressive for proper muscle tissue decellularization. At present, and aiming to preserve the matrix content and tissue structure, some less aggressive detergents, salt solutions, and nucleus-specific enzymes are the preferred decellularization methods. Most of the protocols use weak acids or detergents, such as sodium deoxycholate or Triton X-100 and SDS, respectively, followed by DNase treatment—all of them at low concentrations and exposition times and with multiple repeated cycles [100,101]. In some cases, trypsin is used in low concentrations and for short times, ensuring it does not damage in excess the protein structure.

Tendon tissue is a highly fibroelastic structure that connects muscles to bones. A tendon's ECM is mainly formed of collagen type I, elastin, and proteoglycans, and it provides mechanical and elastic capabilities. Collagen, in particular, constitutes up to 80% of the dry mass of tendons. These proteins are organized by creating fibers, fascicles, and, finally, the tendon itself. Other than that, there is a huge network of proteoglycans and other elastic macromolecules [49].

Tendons have a natural healing capacity, but they can be damaged if the injury goes beyond this healing capacity. Damage to tendons can be the result of severe trauma or the result of continuously repeated injuries during recovery processes [47]. When using a material to repair possible damage, the main properties required are mechanical and elastic capacities. In this context, dECM derivative materials show good regenerative properties, particularly the ones created with decellularized tendons, as they are assimilated easily and promote new tissue formation.

In order to decellularize tendons, detergents are the most commonly used reagents. Triton X-100 and SDS have been tested and compared independently as tendon decellularization methods, with and without a previous freeze–thawing cycle [102]. Triton X-100 treatment shows less efficiency in cell lysis, with no significant cell removal, and induces damage to the tendon structure. On the other hand, SDS is more effective as a tendon decellularization agent, with less damage to the ECM components and collagen structure [102]. Tri-*n*-butyl phosphate (TnBP) detergent has also been used for tendon decellularization purposes, with improved results compared to previous methods. Specifically, TnBP treatment results in a significant decrease in cell density, without disruption of the collagen matrix, even when used in relatively high concentrations [47].

4.5. Cardiovascular Tissue

The heart is a muscular organ whose function is mainly the pumping of blood through the circulatory system. The ECM of the heart is quite specific and is composed predominantly of collagens (types I, II, and III), fibrillin, hyaluronan, laminin, fibronectin, and proteoglycans [34,103,104]. Due to its composition, it shows great strength, flexibility, and durability [105].

Cardiovascular diseases are the target of multiple regenerative medicine approaches. Stem cell-related approaches have been tested as promising therapies for myocardial infarction, chronic ischemic myocardial dysfunction, and nonischemic dilated cardiomyopathy, among others. Moreover, regenerative and repair strategies have also been investigated as alternatives to heart transplant procedures. On the other hand, research efforts are directed toward defining regenerative or reparative approaches as a substitute to heart valve replacement procedures, a clinically required procedure in certain patients of valvular heart disease (VHD). In all of these cardiovascular regenerative research contexts, decellularized cardiac tissue is now thoroughly assayed, sometimes as a biocompatible and cytokine-carrying implantable scaffold, and in other cases, as a recellularized carrier of therapeutic cells [106,107]. Indeed, whole tissue decellularization, followed by recellularization, is a strategy that many labs are working on [108].

In comparison to other tissues, which are hard to decellularize, current methods yield decellularized heart tissue that retains a great number of its original properties, including its elasticity. The most frequent method to achieve heart decellularization is the use of specific detergents combined with other decellularizing agents. Detergents such as SDS, sodium deoxycholate, PEG, or Triton X-100 work very well as decellularization agents in valves, tissue pieces, and in a whole heart decellularization context. These detergents are often used together [76], but they have also been individually compared and optimized. For example, for whole porcine heart decellularization, Ferng et al. suggested 3% SDS as the optimal detergent, especially when perfused at a pressure between 90 and 120 mmHg, while discouraging the use of CHAPS or OGP due to their inability to successfully decellularize the tissue. Physical and enzymatic methods are often used before or after the detergent-based decellularization step. For example, osmotic shock before decellularization induces loosening of the ECM, while pretreatment with trypsin–EDTA also improves further decellularization steps [30,109,110]. After the detergent-based decellularization step(s), and in order to achieve more porosity in the scaffold, hearts are often freeze-dried [109–111], and sucrose may be added to the freezing media in order to avoid damaging or denaturing biomolecules in the heart scaffold [111]. Focused on heart valve decellularization, postdetergent treatment, enzymes at low concentrations have been used in order to remove the waste of nucleic acids [112], a treatment that does not affect collagen valves or elastane and is compatible with further cell seeding strategies [30].

Some authors claim the most common detergents used as decellularizing agents for hearts may cause ECM denaturation and further loss of mechanical properties. That is why some physical and enzymatic treatments have been assayed with no detergent step for heart decellularization. For example, Seo et al. based their study on the supercritical fluid technology using the scCO₂–EtOH cosolvent system to decellularize hearts, showing that the supercritical carbon dioxide method maintains higher GAG and collagen levels in the remaining decellularized scaffolds [113]. For heart valves, in terms of enzymatic methods, an accutase solution, followed by nuclease treatment, has been reported [112], while other proteolytic and collagenolytic enzymes combined with nucleases are also able to effectively remove nearly all nucleic acids [112]. Other methods have been assayed, but seem more controversial in terms of the achieved nucleic acid removal, such as the use of a combination of proteases and chelating agents, e.g., trypsin–ethylenediaminetetraacetic acid [112].

4.6. Vascular Tissue

Vascular tissue is related to the transport of nutrients, oxygen, CO₂, hormones, and blood cells through the body. Essentially, it comprises arteries, arterioles, and veins, while only arteries are the common target for decellularization approaches. Arteries are elastic blood vessels that carry oxygenated blood from the heart to the whole body. The main arteries are composed of three tissue layers, from inside out: intima, media, and adventitia. The tunica intima's ECM contains mainly laminin and collagen type IV, while the medium layer is principally composed of collagen type III, elastin, glycoproteins, and GAGs. In contrast, the ECM of the outermost tunica consists primarily of collagen type I and elastin, but it also contains proteoglycans such as biglycan and decorin, as well

as thrombospondin-2 [114]. Although arteries have a very complex structure, it is very important to maintain the ECM components in the interest of keeping the ECM properties intact, such as elasticity and resistance.

Arterial diseases such as pulmonary arterial hypertension, restenosis, and peripheral arterial diseases are now targeted with experimental and promising stem cell therapies [115–118]. On the other hand, peripheral and coronary artery bypasses are clinical procedures often based on artery replacement by autologous graft transplantation. The use of natural or synthetic biopolymers as grafting materials is a clinically feasible option [119,120], but decellularized artery grafts are gaining increased research attention as artery bypass grafting materials due to their proper molecular and mechanical properties and their reduced immunogenicity [121,122].

Before the artery decellularization technique starts, there are different steps that are recommended for better results. Some protocols suggest to lyse blood cells by washing the arteries in distilled water while shaking [120], while others include three freeze–thaw cycles with EDTA [50]. As in many other tissues, decellularization is mainly based on the activity of detergents such as SDS, EDTA, SDC, CHAPS, Triton X-100, or DOC [27,50,56,120,123,124], used individually or in combination [50]. Some protocols report trypsin and hypo/hypertonic solutions used together with these detergents [27,50,56], while the use of enzymatic DNA and RNA removal as one of the final steps is also recommended [27,56]. All of these chemical methods report quite good results, both in vitro and in vivo, implying the use of detergents as a valuable approach to vascular decellularization, while improvements related to avoiding immunogenicity and cytotoxicity are required [121].

Recently, arterial decellularization mediated by supercritical and pressurized CO₂ has been described. It briefly consists of a high-pressure syringe pump that delivers liquid CO₂ and ethanol or limonene (as cosolvents) through a preheated extraction vessel. Samples are treated with scCO₂ and endonucleases to remove residual cosolvent and DNA. This approach yields a nearly intact decellularized tissue free of cells, lipids, and nucleic acids, proposing an alternative to traditional decellularization methods. Nevertheless, further in vitro and in vivo analyses need to be completed [125].

4.7. Dermal Tissue

The skin's main function is to protect, but it is also in charge of thermoregulation and perception. Dermal tissue is complex, with different layers, such as the epidermis, dermis, and subdermis, each with different compositions, properties, and functions. The epidermis is the outermost layer, and its main function is protection. Behind it, the dermis softens stress and strain, while also provides a sense of touch, elasticity, and heat. The inner layer is the subdermis and it is in charge of insulation. Dermal tissue, as many tissues, is composed of different collagens (85% of the dermal tissue's ECM), matricellular proteins, elastin, fibrillin, and also other fiber-forming proteins, such as vitronectin and fibronectin, which are necessary for wound healing. The ECM of dermal tissue is also formed by proteoglycans and GAGs, with functions related to hydration and osmosis balance. Examples of these are hyaluronic acid, decorin, and versican [126].

Dermal conditions such as cutaneous burns and scars require regenerative medicine approaches to restore dermal function. These therapeutic targets comprise stem cell transplants, growth factors, and tissue engineering. When scars, burns, and wounds are not able to heal on their own, they require replacement of the dermal barrier. It is very common to find skin equivalent and reconstruction research in the literature using primary human fibroblasts and keratinocytes, regularly supplemented with a collagen type I matrix or ascorbate [127,128]. In terms of decellularized approaches, acellular dermal matrices (ADMs) are widely used in clinical regenerative medicine approaches because of their biological and structural organization. ADMs can be of both animal and human origin, and they have a lot of different applications, such as the regeneration of skin tissue in burn, wound, and scar reconstructions, among others.

The majority of commercial ADMs are based on patented or proprietary decellularization protocols. Among the experimental research examples, the first step is always the mechanical isolation of the dermal layer, which is obtained by individual or combined chemical, physical, and biological methods supplemented with agitation. Dermal tissue can be incubated in hypotonic buffer for cell lysing [129] before the dermal decellularization step, which is usually carried out with detergents such as Triton X-100, DOC, N-lauroylsarcosinate (NLS), or SDS, and often in combination with trypsin, BSA, EDTA, and/or dispase [25,76,124,129–132]. Detergents can be also combined with acids and bases for the hydrolytic degradation of residual nucleic acids or even hair, but they can damage the ECM [109]. Some protocols describe the use of a further step in endonucleases treatment to remove residual genetic material [129,132].

It is worth noting that there are some other methods that have been reported that are detergent-free, such as osmotic shock and latrunculin B treatment, but they are not mainstream in the dermal tissue decellularization field [132].

4.8. Tissues Related to Respiratory System

Taking oxygen and expelling carbon dioxide is a function of the respiratory system, which is formed by multiple organs. Some of them, such as the trachea, lungs, and even diaphragm, have been tested as raw materials for decellularization purposes [133–135].

The trachea is related to essential physiological functions, such as airway protection, phonation, and breathing. It is composed of hyaline cartilage, fibrous tissue, respiratory epithelium, and smooth muscle, with cartilage being the most prominent [134]. Trachea damage requiring replacement surgery can be a result of trauma, neoplastic diseases, or congenital stenosis. Tracheal reconstruction in these cases is still a great challenge, while currently, autologous tissue and cell transplantation, with or without additional grafting material, seems the best solution [136,137]. In this sense, decellularized allograft and xenograft trachea is a material that has been tested in *in vivo* settings. While hyaline cartilage is part of this tissue, its decellularization protocols are slightly different to the ones described for cartilage, being tissue freeze-drying, followed by detergent treatment, the most common [138]. Some protocols add DNases into the detergent treatment step to ensure the elimination of the nuclear material. Commonly, mild reagents are used with several cycles of repeated treatment. According to the reports, this procedure yields mild disruption of the mucosa layer, with preservation of the majority of the remaining tissue structure [139].

The function of the lungs is related to gas exchange from the environment to the bloodstream. The structure of the bronchi in the lungs is similar to the trachea, while air circulates from the bronchi to the bronchioles on its way to alveolar airspace, where gas exchange occurs. The regenerative capacity of the lungs is low, and a broad spectrum of severe lung diseases, such as obstructive diseases, fibrosis, and sarcoidosis, may require a lung transplantation procedure [140]. In this context, decellularized lung tissue has been tested as an experimental alternative to transplantation. Perfusion of detergents such as SDS and Triton X-100 is a technique useful to decellularize mouse and rat cadaveric lung tissue, thereby preserving the vascular and airway structures of the tissue [141–143]. Due to the complexity of lung tissue and the need for instant functionality of used implants, a lung's dECM requires recellularization with epithelial and endothelial cells via cell infusion and bioreactors for *ex vivo* generation, maturation, and maintenance of the so-called bioartificial lungs. *In vivo* implantation of these organs in rats yields anastomosis, but long-term success is still to be achieved [143,144].

4.9. Tissues Related to Gastrointestinal Tract

The gastrointestinal tract is a complex microenvironment with different parts and multiple related organs. It is in charge of digesting food to extract energy and nutrients and to absorb them. Damage to the gastrointestinal tract or the related organs can be caused by stress, injury, or diseases that affect one or several tissues of the gastrointestinal tract, for example, trauma, surgeries, neoplasia, cancers, fibrosis, inflammatory bowel disease, esophagectomy, and congenital or acquired defects [145]. The

complex anatomy of the gastrointestinal tract makes the use of bioengineered scaffolds a difficult task, requiring the use of multilayered structures and the seed of different types of cells, depending on the tissue anatomy [146]. The esophagus and intestines have been the main target of decellularization in gastrointestinal tissue, along with the related organs such as the liver and pancreas, and decellularization has often been complemented with the seeding of functional cells [147]. Research of the esophagus and pancreas is still in the initial stages of development [148]; therefore, here, we focus on intestine and liver tissue decellularization.

The intestine has a complex cellular and matrix architecture with multiple gradients, and it is therefore difficult to replicate using simple scaffolds. The three-dimensional architecture of the intestine is maintained by the ECM, composed of an intricate network of fibrous structural proteins (proteoglycans and glycoproteins), along with fibronectin, laminin isoforms, collagens, and heparin sulfate proteoglycans (HSPGs). Furthermore, multiple cell phenotypes are present in the intestine, including stem cells, pericryptal myofibroblasts, fibroblasts, endothelial cells, pericytes, immune cells, neural cells, and smooth muscle cells [149]. The intestinal stem cell niche is a well-known dynamic environment located at the base of crypts and embedded within a specific ECM in which the intestinal stem cells (ISCs) reside and control proliferation, differentiation, and tissue homeostasis. That is why multiple research efforts have been conducted to bioengineer the intestinal stem cell niche, including the use of decellularized tissue [150]. For intestine decellularization, a combination of chemical and enzymatic solutions (perfusion of sodium deoxycholate, use of DNase, immersion in a hypotonic solution, etc.) is used to remove cells in this tissue, while maintaining the 3D structure [151,152]. Recent studies have shown that the integrin effector protein focal adhesion kinase (FAK) is essential for intestinal regeneration, and thus the preservation of FAK in decellularized tissue scaffolds is essential for regenerative purposes [153].

Hydrogels derived from decellularized intestine are useful for generating endoderm-derived human organoids, such as gastric, hepatic, pancreatic, and small intestine organoids [154]. Moreover, decellularized intestine scaffolds have been used for regenerative purposes in many other tissues, due to their intrinsic ability to induce site-specific *in vivo* cellular repopulation and regeneration without the need for an *in vitro* recellularization step. For example, decellularized intestine has been used for regeneration purposes in vascular [155], cardiac [156], dura mater [157], abdominal wall [158], bladder [159], bowel [160], corneal [161], esophagus [162], tendon [163], ligament, cartilage (meniscus) [164], dermal [165], and bone tissues [166].

In recent decades, several methods have been implemented for liver decellularization, aiming to preserve the liver's major ECM components such as laminin, elastin, fibronectin, collagen types I and IV, and sulfated glycosaminoglycan (sGAG) [167]. The most promising of such methods is the perfusion decellularization method, in which detergents (SDS and/or Triton X-100), hyperosmotic (NaCl), and enzymatic (DNase) solutions are injected intravascularly [168]. Additionally, liver fragments can be immersed into the detergent solutions under mechanical agitation, and the previously described detergent–enzymatic method can be combined with high G-force oscillation treatment to reduce processing times. In such decellularized livers, the structural properties and the protein composition of the ECM are maintained, while they show good biocompatibility and neovascularization *in vivo* [168,169].

4.10. Nervous Tissue

The nervous system is a complex system of specialized cells that connect the parts of the body and coordinate it using signals. The main cells that transmit said signals are neurons, while they require a network of nonneural supportive cells, i.e., glia cells. In this context, the nervous tissue's ECM is indeed created by glia cells, which protect, isolate, and feed neurons, thereby allowing synapsis. The main structural components of the ECM are collagen (types II and IV) and laminin. Fibronectin guides axon growth, and acetylcholinesterase helps to regulate neural signals [170].

Damage of the nervous system can be caused by multiple conditions, diseases, and injuries, while symptoms related to tissue damage can be multiple, from mild to severe, including the loss of motor functions [171]. The regeneration of damaged nerve connections is a long-time pursued aim and it has been widely assayed using different approaches. There is consensus in defining the properties of the ideal graft for nerve regeneration, which should be of a flexible, thin, neuro-inductive, conductive, and biocompatible structure, capable of promoting axon proliferation and of guiding its growth toward the reconnection of damaged nervous edges [172,173]. To do this, the structure should be able to be molded by Schwann cells, which are specific glia cells related to the guidance of neural regeneration processes. In this context, the usefulness of dECM-derived nerve scaffolds as implantable grafts has been assessed in *in vitro* and *in vivo* animal trials, with some promising results [174]. Some studies have shown the capacity of the dECM to promote axon growth and the regeneration of peripheral nerve connections in rats [69,172,175]. The regeneration process requires weeks, and the subjects are in need of rehabilitation in order to begin proper recovery.

For decellularization of nervous tissue, the most commonly used approach is washing with detergents. Note that in the peripheral nerves, the main DNA source is that of Schwann cells, which protect the axons that carry signals. The detergent that shows the best results in this tissue is usually Triton X-200 [28]. A low concentration and prolonged Triton X-200 treatment has been proven successful in eliminating both the axon and Schwann cells, as well as myelin waste. The elimination causes slight damage to the ECM proteins, but it retains good condition of the structure. This treatment is commonly used in combination with an osmotic cell burst, which breaks the cells, facilitating cell waste removal by Triton X-200. Other detergents, such as SDS or Triton-100, are used without osmotic shock [33,171]. Other than these, nucleases have been used in combination with detergents and osmotic methods to ensure that the DNA is properly removed.

4.11. Cornea

The cornea is a transparent, avascular, and highly innervated connective tissue that acts as the primary structural barrier to infections, and is the first lens of the eye optical system. The human cornea is organized in five layers, three of which are cellular (i.e., the epithelium, stroma, and endothelium), and two are considered interphases (i.e., the Bowman membrane and the Descemet membrane). This highly organized structure contributes to the cornea's transparency and mechanical strength, while disruptions to this pattern disturb said transparency and result in loss of vision [176,177]. The cornea's ECM is composed of water, inorganic salts, proteoglycans, glycoproteins, and collagens. The stromal lamellar collagen fibrils are heterotypic hybrids of types I and V, with significant amounts of collagen types VI, XII, and XIV. A high concentration of small leucine-rich proteoglycans, including decorin, lumican, and keratan, decorated with dermatan sulfate and keratan sulfate are present in the lamellae, credited with maintaining the interfibrillar spacing required for transparency, and contributing to the regulation of corneal hydration.

Many corneal disorders require a corneal transplant, while obviously there is limited availability of donor tissue. As an alternative to cadaveric corneas, among others, the dECM from acellular porcine and bovine cornea and decellularized amniotic membrane have been combined with different cell types to form full-thickness corneas with stroma, epithelium, and endothelium layers [178–180]. This dECM replicates the structure and functional requirements of the native cornea, with the maintenance of the collagen fibril organization, transparency, biocompatibility, suitable mechanical toughness, and low immunogenicity [181,182].

Detergents such as SDS and Triton X-100 were commonly used in the pioneering cornea decellularization methods. Du et al. used a 24 h SDS (0.5% or 1%) treatment to generate a decellularized porcine cornea matrix, which was opaque and swollen after the decellularization [48]. Transparency was restored after soaking in sterile glycerol for one hour, but implantation in a rabbit model showed stromal edema and worsening of corneal opacity throughout the 28-day observation period. Another comparative study used NaCl, 0.05% SDS, or 1% Triton-X100 to decellularize

human corneas, and observed that NaCl did not affect transparency, while Triton-X-treated corneas experiencing tissue clouding; meanwhile, SDS-treated corneas appeared the most cloudy/opaque after decellularization [183,184]. Conversely, SDS treatment was combined with benzonase (nuclease) and protease inhibitors in human corneal sheets; in this case, when the dECM was recellularized and implanted in a rabbit model, the implanted tissue maintained complete transparency for three months [185]. A conceptually similar decellularization approach combines sodium N-lauroyl glutamate (SLG) surfactant with supernuclease (a nuclease homologous to benzonase), and also provides adequate transparency and good biocompatibility without degradation 28 days after transplantation [57].

Benzonase endonuclease is often used as the main decellularizing agent in a detergent-free approach, based on its ability to quickly infiltrate the corneal stroma, combined with its easy removal by repeated washes. This approach minimizes the destruction of the ECM, with minimal loss of optical transparency and proper results in animal transplantation assays [186].

4.12. Thymus

The thymus is an innervated organ part of the lymphatic and endocrine systems. The function of the thymus is to allow the development and maturation of the T-cell repertoire, and therefore, it has a main role in the immune response. Specifically, T-cell precursors are generated in the bone marrow and migrate to the thymus to become thymocytes, ultimately maturing immunocompetent T-cells. Endothelial and epithelial cells are the main cellular components of the thymus and, along with thymocytes, contribute to creating specific ECMs and microenvironment. The complex interaction network in the thymus includes cytokines, chemokines, matrix metalloproteases, laminin, collagen type IV, and multiple isoforms of fibronectin and glycoproteins, among others, with specific roles and precisely tuned toward the T-cell development process.

Thymus organ cultures are achieved via serial disaggregation and reaggregation of the tissue, and they are useful for *ex vivo* study of thymus function and complex cell interactions [187]. The rationale of thymus decellularization is mainly related to modeling thymus development, as well as the generation of potential regenerative or therapeutic approaches for *in vivo* immune response modulation [188]. To this aim, decellularization should be soft enough to keep intact the key ECM components, and should allow further proper recellularization with thymic epithelial cells and endothelial cells. Specifically, the thymus's dECM-derived bioengineered structure has to be able to reproduce T-cell differentiation and maturation processes. Freeze–thawing, followed by SDS and Triton X-100 detergent treatments, is a common decellularization technique [189]. Thymic epithelial cell-seeded dECM scaffolds, also called thymic reconstructed organoids, have been implanted in immunocompromised mice, yielding the development of populations of mature T-cells otherwise absent in these animals [190].

5. The Clinical Outcome and Market of the dECM

Translational research is already a reality for some dECM-derived approaches, including several ongoing clinical trials and products on the market (see Table 2). The most common products are decellularized tissue pieces, serving as implantable materials for tissue formation, with proprietary- or patented-specific decellularization procedures [191–193].

Decellularized products on the market are generally issued with the ISO standard for biological medical devices (ISO10993-1, the standard for biological evaluation of medical devices), while recently, a specific standard for the evaluation of decellularized products has become available (ASTM F3354-19, Standard Guide for Evaluating Extracellular Matrix Decellularization Processes) [8]. Characterization includes *in vitro* and *in vivo* studies to provide data related to the removal of donor DNA and to the safety of implantable commercial products [194,195].

For some specific tissues, there are multiple decellularized products, competing for the same application market and claiming different properties due to differences in decellularization treatments. Comparative clinical case studies are common, and they provide useful information related to clinical success and outcomes of the different commercial dECMs available for each specific application [196–

199]. In this sense, there is a lack of standardized tissue-specific decellularization methods, which would serve as the standard control for comparative purposes [5,200]. Such standardized controls would be useful not only for the assessment of products already on the market, but also to perform more efficient, comparable, and reliable experimental research studies [201].

Table 2. Some examples of commercially available tissue-derived ECM products provided by tissue source.

Tissue Source	Application	Examples of Commercial Products
Bone/cartilage tissues	Grafting material for tissue regeneration and orthopedic surgery	-AlloWedge [®] Bicortical Allograft Bone (RTI Surgical) -Chondrofix [®] Osteochondral Allograft (Zimmer Inc.) -BioAdapt [®] DBM (RTI Surgical)
Adipose tissue	Aesthetic soft tissue reconstruction. Multiple tissues.	-Leneva [®] Allograft adipose matrix (MTF Biologics) -Adipose allograft matrix (AAM) (Musculoskeletal Transplant Found.)
Muscle and tendons	Graft tissue for pelvic organ prolapse	-Suspend [®] (Coloplast Corp.)
Cardiovascular tissue: heart valve, Pericardium	Graft for valve replacement and aneurysm reconstruction	-Hancock [®] II, Mosaic [®] and Freestyle [®] (Medtronic Inc.) -Prima [®] Plus and Perimount [®] (Edwards Lifesciences LLC) -Epic [®] and SJM Biocor [®] (St. Jude Medical Inc.)
Vascular tissue: Descending aorta, carotid artery, mesenteric vein, femoral artery.	Xenografting material for arterial replacement, bypass, aneurysm reconstruction, and path graft	-Artegraft [®] (Artegraft Inc.) -CryoGraft [®] and CryoArtery [®] (CryoLife Inc.) -ProCol [®] (LeMaitre Vascular Inc.)
Nerve tissue	Surgical repair of peripheral nerve discontinuities.	-Avance nerve allograft (Axogen corporation)
Dermal tissue	Grafting matrix for damaged tissue repair	-Dermacell [®] AWM (LifeNet Health Inc) -Alloderm [®] RTM (BioHorizons) -AlloPatch HD [®] (MTF Biologics)
Gastrointestinal tract: small intestine	Xenograft for cardiac tissue repair	-CorMatrix ECM [®] (CorMatrix [®] Cardiovascular Inc.)
Others: amniotic membrane, peritoneum	Grafting matrix for damaged tissue repair	-Biovance [®] (Celgene Cellular Therapeutics) -Meso BioMatrix [®] Surgical Mesh (MTF Biologics)

6. Concluding Remarks

Decellularization is a great technique to generate tissue-specific ECM-derived products with multiple applications, including tissue regeneration in clinical settings. Decellularization can be achieved from many tissues, but it has to be designed in accordance with the properties of the target tissue and the intended approach, aiming to preserve specific ECM components. The literature is extensive, but mostly related to empirical experimental research data. As a consequence, a variety of decellularization protocols have been described for each one of the targeted tissues. Therefore, the challenge remains in defining broadly acceptable standardized decellularization and characterization procedures for each specific tissue that would ease the selection of standard controls and the development of future research, ultimately helping in the transfer of knowledge to clinical settings. At present, tissues' dECM scaffolds are the core of most clinical products, while research efforts are now strongly moving toward the development of postprocessing-related products, such as

bioink-related 3D structures. Therefore, we anticipate rapid growth in the number of tissue-specific dECM postprocessing-related clinical products for the coming years.

Author Contributions: Conceptualization, U.M. and A.A.; writing—original draft preparation, U.M. and R.R.-H., S.R.-C., N.G.-U., and A.A.; writing—review and editing, A.A.; visualization, B.O.-G.; supervision, A.A. All authors have read and agreed to the published version of the manuscript.

Funding: This work was supported by the Spanish “Programa Estatal de I+D+i Orientada a los Retos de la Sociedad”, grant number RTI2018-101708-A-I00. S.R.-C. was supported by Fomento de San Sebastian innovative talent programme, grant number 0508/2019/0009. R.R.-H. was supported by Spanish State Training Subprogramme, grant number PRE2018-084542. A.A. was supported by Spanish State Subprogramme of Incorporation Ramón y Cajal, grant number RYC2018-025502-I, and 2019 Leonardo Grant for Researchers and Cultural Creators, BBVA Foundation, grant number IN[19]_CMA_BIO_0119. The BBVA Foundation accepts no responsibility for the opinions, statements and contents included, which are entirely the responsibility of the authors.

Acknowledgments: This work was performed under the Maria de Maeztu Units of Excellence Programme—Grant No. MDM-2017-0720 Ministry of Science, Innovation and Universities. And Basque Government Elkartek program (KK-2019/00093).

Conflicts of Interest: The authors declare no conflicts of interest. The funders had no role in the design of the study; in the collection, analyses, or interpretation of data; in the writing of the manuscript, or in the decision to publish the results.

Abbreviations

ECM	Extracellular matrix
dECM	Decellularized extracellular matrix
3D	Three-dimensional
DNA	Deoxyribonucleic acid
GAG	Glycosaminoglycans
SDS	Sodium dodecyl sulfate
CHAPS	3-[(3-cholamidopropyl)dimethylammonio]-1-propanesulfonate
EDTA	Ethylenediaminetetraacetic acid
VAD	Vacuum-assisted decellularization
HA	Calcium hydroxyapatite
MMP	Matrix metalloprotease
BMPs	Bone morphogenetic proteins
DBM	Demineralized bone matrix
DecBM	Decellularized bone matrix
HCl	Hydrochloric acid
ChABC	Chondroitinase ABC
TnBP	Tri-n-butyl phosphate
VHD	Valvular heart disease
PEG	Polyethylene glycol
OGP	n-Octyl- β -D-glucoopyranosid
DOC	Deoxycholic acid
SDC	Sodium deoxycholate
ADMs	Acellular dermal matrices
NLS	N-lauroyl sarcosinate
HSPGs	Heparin sulfate proteoglycans
ISCs	Intestinal stem cells
FAK	Focal adhesion kinase
sGAG	Sulfated glycosaminoglycan
SLG	Sodium N-lauroyl glutamate
ISO	International Organization for Standardization
ASTM	American Society of Testing and Materials

References

1. Gattazzo, F.; Urciuolo, A.; Bonaldo, P. Extracellular matrix: A dynamic microenvironment for stem cell niche. *Biochim. Biophys. Acta Gen. Subj.* **2014**, *1840*, 2506–2519. [[CrossRef](#)] [[PubMed](#)]
2. Hussey, G.S.; Dziki, J.L.; Badylak, S.F. Extracellular matrix-based materials for regenerative medicine. *Nat. Rev. Mater.* **2018**, *3*, 159–173. [[CrossRef](#)]
3. Ahmed, E.M. Hydrogel: Preparation, characterization, and applications: A review. *J. Adv. Res.* **2015**, *6*, 105–121. [[CrossRef](#)] [[PubMed](#)]
4. Porzionato, A.; Stocco, E.; Barbon, S.; Grandi, F.; Macchi, V.; De Caro, R. Tissue-engineered grafts from human decellularized extracellular matrices: A systematic review and future perspectives. *Int. J. Mol. Sci.* **2018**, *19*, 4117. [[CrossRef](#)] [[PubMed](#)]
5. Crapo, P.M.; Gilbert, T.W.; Badylak, S.F. An overview of tissue and whole organ decellularization processes. *Biomaterials* **2012**, *32*, 3233–3243. [[CrossRef](#)]
6. Parmaksiz, M.; Dogan, A.; Odabas, S.; El, A.E.; El, Y.M. Clinical applications of decellularized extracellular matrices for tissue engineering and regenerative medicine. *Biomed. Mater.* **2016**, *11*, 22003. [[CrossRef](#)]
7. Nakamura, N.; Kimura, T.; Kishida, A. Overview of the Development, Applications, and Future Perspectives of Decellularized Tissues and Organs. *Biomaterials* **2017**, *3*, 1236–1244. [[CrossRef](#)]
8. ASTM International. *ASTM F3354-19, Standard Guide for Evaluating Extracellular Matrix Decellularization Processes*; ASTM International: West Conshohocken, PA, USA, 2019.
9. Woods, T.; Gratzner, P.F. Effectiveness of three extraction techniques in the development of a decellularized bone-anterior cruciate ligament-bone graft. *Biomaterials* **2005**, *26*, 7339–7349. [[CrossRef](#)]
10. Choi, J.S.; Kim, B.S.; Kim, J.Y.; Kim, J.D.; Choi, Y.C.; Yang, H.J.; Park, K.; Lee, H.Y.; Cho, Y.W. Decellularized extracellular matrix derived from human adipose tissue as a potential scaffold for allograft tissue engineering. *J. Biomed. Mater. Res. Part A* **2011**, *97*, 292–299. [[CrossRef](#)]
11. Bautista, C.A.; Park, H.J.; Mazur, C.M.; Aaron, R.K.; Bilgen, B. Effects of Chondroitinase ABC-Mediated Proteoglycan Digestion on Decellularization and Recellularization of Articular Cartilage. *PLoS ONE* **2016**, *11*, e0158976. [[CrossRef](#)]
12. Yu, Y.; Hua, S.; Yang, M.; Fu, Z.; Teng, S.; Niu, K.; Zhao, Q.; Yi, C. Fabrication and characterization of electrospinning/3D printing bone tissue engineering scaffold. *RSC Adv.* **2016**, *6*, 110557–110565. [[CrossRef](#)]
13. Heath, D.E. A Review of Decellularized Extracellular Matrix Biomaterials for Regenerative. *Regen. Med. Transl. Med.* **2019**, *5*, 155–166. [[CrossRef](#)]
14. Kabirian, F.; Mozafari, M. Decellularized ECM-derived bioinks: Prospects for the future. *Methods* **2019**, *171*, 108–118. [[CrossRef](#)] [[PubMed](#)]
15. Taylor, D.A.; Sampaio, L.C.; Ferdous, Z.; Gobin, A.S.; Taite, L.J. Decellularized matrices in regenerative medicine. *Acta Biomater.* **2018**, *74*, 74–89. [[CrossRef](#)] [[PubMed](#)]
16. Choudhury, D.; Tun, H.W.; Wang, T.; Naing, M.W. Organ-Derived Decellularized Extracellular Matrix: A Game Changer for Bioink Manufacturing? *Trends Biotechnol.* **2018**, *36*, 787–805. [[CrossRef](#)] [[PubMed](#)]
17. Gilpin, A.; Yang, Y. Decellularization Strategies for Regenerative Medicine: From Processing Techniques to Applications. *Biomed Res. Int.* **2017**, *2017*, 9831534. [[CrossRef](#)] [[PubMed](#)]
18. Robb, K.P.; Shridhar, A.; Flynn, L.E. Decellularized Matrices as Cell-Instructive Scaffolds to Guide Tissue-Specific Regeneration. *ACS Biomater. Sci. Eng.* **2018**, *4*, 3627–3643. [[CrossRef](#)]
19. Spang, M.T.; Christman, K.L. Extracellular matrix hydrogel therapies: In vivo applications and development. *Acta Biomater.* **2017**, *68*, 1–14. [[CrossRef](#)]
20. Keane, T.J.; Swinehart, I.T.; Badylak, S.F. Methods of tissue decellularization used for preparation of biologic scaffolds and in vivo relevance. *Methods* **2015**, *84*, 25–34. [[CrossRef](#)]
21. Crapo, P.M.; Gilbert, T.W.; Badylak, S.F. An overview of tissue and whole organ decellularization processes. *Biomaterials* **2011**, *32*, 3233–3243. [[CrossRef](#)]
22. White, L.J.; Taylor, A.J.; Faulk, D.M.; Keane, T.J.; Saldin, L.T.; Reing, J.E.; Swinehart, I.T.; Turner, N.J.; Ratner, B.D.; Stephen, F. The impact of detergents on the tissue decellularization process: A ToF-SIMS study. *Acta Biomater.* **2017**, 207–219. [[CrossRef](#)] [[PubMed](#)]
23. Cartmell, J.S.; Dunn, M.G. Effect of chemical treatments on tendon cellularity and mechanical properties. *J. Biomed. Mater. Res.* **2000**, *49*, 134–140. [[CrossRef](#)]

24. Elder, B.D.; Kim, D.H.; Athanasiou, K.A. Developing an articular cartilage decellularization process toward facet joint cartilage replacement. *Neurosurgery* **2010**, *66*, 722–727. [[CrossRef](#)] [[PubMed](#)]
25. Chen, R.N.; Ho, H.O.; Tsai, Y.T.; Sheu, M.T. Process development of an acellular dermal matrix (ADM) for biomedical applications. *Biomaterials* **2004**, *25*, 2679–2686. [[CrossRef](#)] [[PubMed](#)]
26. Tavassoli, A.; Matin, M.M.; Niaki, M.A.; Mahdavi-Shahri, N.; Shahabipour, F. Mesenchymal stem cells can survive on the extracellular matrix-derived decellularized bovine articular cartilage scaffold. *Iran. J. Basic Med. Sci.* **2015**, *18*, 1221. [[PubMed](#)]
27. Dahl, S.L.M.; Koh, J.; Prabhakar, V.; Niklason, L.E. Decellularized native and engineered arterial scaffolds for transplantation. *Cell Transplant.* **2003**, *12*, 659–666. [[CrossRef](#)]
28. Hudson, T.W.; Liu, S.Y.; Schmidt, C.E. Engineering an improved acellular nerve graft via optimized chemical processing. *Tissue Eng.* **2004**, *10*, 1346–1358. [[CrossRef](#)]
29. McFetridge, P.S.; Daniel, J.W.; Bodamyali, T.; Horrocks, M.; Chaudhuri, J.B. Preparation of porcine carotid arteries for vascular tissue engineering applications. *J. Biomed. Mater. Res. Part A* **2004**, *70*, 224–234. [[CrossRef](#)]
30. Rieder, E.; Kasimir, M.T.; Silberhumer, G.; Seebacher, G.; Wolner, E.; Simon, P.; Weigel, G. Decellularization protocols of porcine heart valves differ importantly in efficiency of cell removal and susceptibility of the matrix to recellularization with human vascular cells. *J. Thorac. Cardiovasc. Surg.* **2004**, *127*, 399–405. [[CrossRef](#)]
31. Poon, C.J.; Pereira, M.V.; Cotta, E.; Sinha, S.; Palmer, J.A.; Woods, A.A.; Morrison, W.A.; Abberton, K.M. Preparation of an adipogenic hydrogel from subcutaneous adipose tissue. *Acta Biomater.* **2013**, *9*, 5609–5620. [[CrossRef](#)]
32. Reing, J.E.; Brown, B.N.; Daly, K.A.; Freund, J.M.; Gilbert, T.W.; Hsiong, S.X.; Huber, A.; Kullas, K.E.; Tottey, S.; Wolf, M.T.; et al. The effects of processing methods upon mechanical and biologic properties of porcine dermal extracellular matrix scaffolds. *Biomaterials* **2010**, *31*, 8626–8633. [[CrossRef](#)] [[PubMed](#)]
33. Cornelison, R.C.; Wellman, S.M.; Park, J.H.; Porvasnik, S.L.; Song, Y.H.; Wachs, R.A.; Schmidt, C.E. Development of an apoptosis-assisted decellularization method for maximal preservation of nerve tissue structure. *Acta Biomater.* **2018**, *77*, 116–126. [[CrossRef](#)] [[PubMed](#)]
34. Ott, H.C.; Matthiesen, T.S.; Goh, S.; Black, L.D.; Kren, S.M.; Netoff, T.I.; Taylor, D.A. Perfusion-decellularized matrix: Using nature's platform to engineer a bioartificial heart. *Nat. Med.* **2008**, *14*, 213–221. [[CrossRef](#)]
35. Burk, J.; Erbe, I.; Berner, D.; Kacza, J.; Kasper, C.; Pfeiffer, B.; Winter, K.; Brehm, W. Freeze-Thaw cycles enhance decellularization of large tendons. *Tissue Eng. Part C Methods* **2014**, *20*, 276–284. [[CrossRef](#)] [[PubMed](#)]
36. Jackson, D.W.; Windler, G.E.; Simon, T.M. Intraarticular reaction associated with the use of freeze-dried, ethylene oxide-sterilized bone-patella tendon-bone allografts in the reconstruction of the anterior cruciate ligament. *Am. J. Sports Med.* **1990**, *18*, 1–11. [[CrossRef](#)] [[PubMed](#)]
37. Roth, S.P.; Glauche, S.M.; Plenge, A.; Erbe, I.; Heller, S.; Burk, J. Automated freeze-thaw cycles for decellularization of tendon tissue—A pilot study. *BMC Biotechnol.* **2017**, *17*, 1–10. [[CrossRef](#)] [[PubMed](#)]
38. Hung, S.H.; Su, C.H.; Lee, F.P.; Tseng, H. Larynx Decellularization: Combining Freeze-Drying and Sonication as an Effective Method. *J. Voice* **2013**, *27*, 289–294. [[CrossRef](#)]
39. Lin, P.; Chan, W.C.; Badylak, S.F.; Bhatia, S.N. Assessing Porcine Liver-Derived Biomatrix for Hepatic Tissue Engineering. *Tissue Eng.* **2004**, *10*, 1042–1053. [[CrossRef](#)]
40. Starnecker, F.; König, F.; Hagl, C.; Thierfelder, N. Tissue-engineering acellular scaffolds—The significant influence of physical and procedural decellularization factors. *J. Biomed. Mater. Res. Part B Appl. Biomater.* **2018**, *106*, 153–162. [[CrossRef](#)]
41. Azhim, A.; Ono, T.; Fukui, Y.; Morimoto, Y.; Furukawa, K.; Ushida, T. Preparation of Decellularized Meniscal Scaffolds Using Sonication Treatment for Tissue Engineering. In Proceedings of the 2013 35th Annual International Conference of the IEEE Engineering in Medicine and Biology Society (EMBC), Osaka, Japan, 3–7 July 2013; pp. 6953–6956.
42. Butler, C.R.; Hynds, R.E.; Crowley, C.; Gowers, K.H.; Partington, L.; Hamilton, N.J.; Carvalho, C.; Platé, M.; Samuel, E.R.; Burns, A.J.; et al. Vacuum-assisted decellularization: An accelerated protocol to generate tissue-intestine in mice. *Biomaterials* **2017**, *124*, 95–105. [[CrossRef](#)]
43. Waletzko, J.; Dau, M.; Seyfarth, A.; Springer, A.; Frank, M.; Bader, R.; Jonitz-heincke, A. Devitalizing Effect of High Hydrostatic Pressure on Human Cells—Influence on Cell Death in Osteoblasts and Chondrocytes. *Int. J. Mol. Sci.* **2020**, *21*, 3836. [[CrossRef](#)] [[PubMed](#)]

44. Gardin, C.; Ricci, S.; Ferroni, L.; Guazzo, R.; Sbricoli, L.; De Benedictis, G.; Finotti, L.; Isola, M.; Bressan, E.; Zavan, B. Decellularization and delipidation protocols of bovine bone and pericardium for bone grafting and guided bone regeneration procedures. *PLoS ONE* **2015**, *10*, e0132344. [[CrossRef](#)] [[PubMed](#)]
45. Rothrauff, B.B.; Yang, G.; Tuan, R.S. Tissue-specific bioactivity of soluble tendon-derived and cartilage-derived extracellular matrices on adult mesenchymal stem cells. *Stem Cell Res. Ther.* **2017**, *8*, 1–17. [[CrossRef](#)] [[PubMed](#)]
46. Lee, D.J.; Diachina, S.; Lee, Y.T.; Zhao, L.; Zou, R.; Tang, N.; Han, H.; Chen, X.; Ko, C.C. Decellularized bone matrix grafts for calvaria regeneration. *J. Tissue Eng.* **2016**, *7*, 2041731416680306. [[CrossRef](#)] [[PubMed](#)]
47. Yang, G.; Rothrauff, B.B.; Tuan, R.S. Tendon and ligament regeneration and repair: Clinical relevance and developmental paradigm. *Birth Defects Res. Part C Embryo Today Rev.* **2013**, *99*, 203–222. [[CrossRef](#)]
48. Du, L.; Wu, X. Development and characterization of a full-thickness acellular porcine cornea matrix for tissue engineering. *Artif. Organs* **2011**, *35*, 691–705. [[CrossRef](#)]
49. Kannus, P. Structure of the tendon connective tissue. *Scand. J. Med. Sci. Sport.* **2000**, *10*, 312–320. [[CrossRef](#)]
50. Cheng, J.; Wang, C.; Gu, Y. Combination of freeze-thaw with detergents: A promising approach to the decellularization of porcine carotid arteries. *Biomed. Mater. Eng.* **2019**, *30*, 191–205. [[CrossRef](#)]
51. Chan, B.P.; Leong, K.W. Scaffolding in tissue engineering: General approaches and tissue-specific considerations. *Eur. Spine J.* **2008**, *17*, 467–479. [[CrossRef](#)]
52. Urist, M.R. Bone: Formation by Autoinduction. *Science* **1965**, *150*, 893–899. [[CrossRef](#)]
53. Rothrauff, B.B.; Tuan, R.S. Decellularized bone extracellular matrix in skeletal tissue engineering. *Biochem. Soc. Trans.* **2020**, *48*, 755–764. [[CrossRef](#)] [[PubMed](#)]
54. Chen, G.; Lv, Y. Decellularized Bone Matrix Scaffold for Bone Regeneration. *Methods Mol. Biol.* **2017**, *1577*, 239–254. [[CrossRef](#)]
55. Cheung, H.K.; Han, T.T.Y.; Marecak, D.M.; Watkins, J.F.; Amsden, B.G.; Flynn, L.E. Composite hydrogel scaffolds incorporating decellularized adipose tissue for soft tissue engineering with adipose-derived stem cells. *Biomaterials* **2014**, *35*, 1914–1923. [[CrossRef](#)]
56. Lin, C.H.; Hsia, K.; Tsai, C.H.; Ma, H.; Lu, J.H.; Tsay, R.Y. Decellularized porcine coronary artery with adipose stem cells for vascular tissue engineering. *Biomed. Mater.* **2019**, *14*. [[CrossRef](#)] [[PubMed](#)]
57. Dong, M.; Zhao, L.; Wang, F.; Hu, X.; Li, H.; Liu, T.; Zhou, Q.; Shi, W. Rapid porcine corneal decellularization through the use of sodium N-lauroyl glutamate and supernuclease. *J. Tissue Eng.* **2019**, *10*, 2041731419875876. [[CrossRef](#)] [[PubMed](#)]
58. Sutherland, A.J.; Detamore, M.S. Bioactive Microsphere-Based Scaffolds Containing Decellularized Cartilage. *Macromol. Biosci.* **2015**, *15*, 979–989. [[CrossRef](#)] [[PubMed](#)]
59. Hashimoto, Y.; Funamoto, S.; Kimura, T.; Nam, K.; Fujisato, T.; Kishida, A. The effect of decellularized bone/bone marrow produced by high-hydrostatic pressurization on the osteogenic differentiation of mesenchymal stem cells. *Biomaterials* **2011**, *32*, 7060–7067. [[CrossRef](#)]
60. Rutala, W.A.; Weber, D.J. Disinfection, sterilization, and antisepsis: An overview. *Am. J. Infect. Control* **2016**, *44*, e1–e6. [[CrossRef](#)]
61. Rogers, W.J. *Steam and Dry Heat Sterilization of Biomaterials and Medical Devices*; Elsevier Masson SAS: Issy les Moulineaux, France, 2012; pp. 20–55.
62. Gosztyla, C.; Ladd, M.R.; Werts, A.; Fulton, W.; Johnson, B.; Sodhi, C.; Hackam, D.J.; Physiology, C. A comparison of sterilization techniques for production of decellularized engineered human tracheal scaffolds. *Biomaterials* **2017**, *124*, 95–105. [[CrossRef](#)]
63. Singh, R.; Singh, D.; Singh, A. Radiation sterilization of tissue allografts: A review. *World J. Radiol.* **2016**, *8*, 355. [[CrossRef](#)]
64. White, L.J.; Keane, T.J.; Smoulder, A.; Zhang, L.; Castleton, A.A.; Reing, J.E.; Turner, N.J.; Dearth, C.L.; Badylak, S.F. The impact of sterilization upon extracellular matrix hydrogel structure and function. *J. Immunol. Regen. Med.* **2018**, *2*, 11–20. [[CrossRef](#)]
65. Van Nooten, G.; Somers, P.; Cuvelier, C.A.; De Somer, F.; Cornelissen, M.; Cox, E.; Verloo, M.; Chiers, K. Gamma radiation alters the ultrastructure in tissue-engineered heart valve scaffolds. *Tissue Eng. Part A* **2009**, *15*, 3597–3604. [[CrossRef](#)]
66. Harrell, C.R.; Djonov, V.; Fellabaum, C.; Volarevic, V. Risks of using sterilization by gamma radiation: The other side of the coin. *Int. J. Med. Sci.* **2018**, *15*, 274–279. [[CrossRef](#)] [[PubMed](#)]

67. Hodde, J.; Janis, A.; Ernst, D.; Zopf, D.; Sherman, D.; Johnson, C. Effects of sterilization on an extracellular matrix scaffold: Part I. Composition and matrix architecture. *J. Mater. Sci. Mater. Med.* **2007**, *18*, 537–543. [[CrossRef](#)] [[PubMed](#)]
68. Galeano, S.; García-Lorenzo, M.L. Bone mineral change during experimental calcination: An X-ray diffraction study. *J. Forensic Sci.* **2014**, *59*, 1602–1606. [[CrossRef](#)] [[PubMed](#)]
69. Lin, T.; Liu, S.; Chen, S.; Qiu, S.; Rao, Z.; Liu, J.; Zhu, S.; Yan, L.; Mao, H.; Zhu, Q.; et al. Hydrogel derived from porcine decellularized nerve tissue as a promising biomaterial for repairing peripheral nerve defects. *Acta Biomater.* **2018**, *73*, 326–338. [[CrossRef](#)] [[PubMed](#)]
70. Sawkins, M.J.; Bowen, W.; Dhadda, P.; Markides, H.; Sidney, L.E.; Taylor, A.J.; Rose, F.R.A.J.; Badylak, S.F.; Shakesheff, K.M.; White, L.J. Hydrogels derived from demineralized and decellularized bone extracellular matrix. *Acta Biomater.* **2013**, *9*, 7865–7873. [[CrossRef](#)]
71. Bracey, D.N.; Seyler, T.M.; Jinnah, A.H.; Lively, M.O.; Willey, J.S.; Smith, T.L.; Van Dyke, M.E.; Whitlock, P.W. A decellularized porcine xenograft-derived bone scaffold for clinical use as a bone graft substitute: A critical evaluation of processing and structure. *J. Funct. Biomater.* **2018**, *9*, 45. [[CrossRef](#)]
72. Kim, Y.S.; Majid, M.; Melchiorri, A.J.; Mikos, A.G. Applications of decellularized extracellular matrix in bone and cartilage tissue engineering. *Bioeng. Transl. Med.* **2019**, *4*, 83–95. [[CrossRef](#)]
73. Khalpey, Z. Acellular porcine heart matrices: Whole organ decellularization with 3D-Bioscaffold & vascular preservation. *J. Clin. Transl. Res.* **2017**, *3*, 260–270. [[CrossRef](#)]
74. Senn, N. On the healing of aseptic bone cavities by implantation of antiseptic decalcified bone. *Am. J. Med. Sci.* **1889**, *3*, 219. [[CrossRef](#)]
75. Gruskin, E.; Doll, B.A.; Futrell, F.W.; Schmitz, J.P.; Hollinger, J.O. Demineralized bone matrix in bone repair: History and use. *Adv. Drug Deliv. Rev.* **2012**, *64*, 1063–1077. [[CrossRef](#)] [[PubMed](#)]
76. Saldin, L.T.; Cramer, M.C.; Velankar, S.S.; White, L.J.; Badylak, S.F. Extracellular matrix hydrogels from decellularized tissues: Structure and function. *Acta Biomater.* **2017**, *49*, 1–15. [[CrossRef](#)] [[PubMed](#)]
77. Kim, D.K.; In Kim, J.; Sim, B.R.; Khang, G. Bioengineered porous composite curcumin/silk scaffolds for cartilage regeneration. *Mater. Sci. Eng. C* **2017**, *78*, 571–578. [[CrossRef](#)] [[PubMed](#)]
78. Elder, B.D.; Vigneswaran, K.; Athanasiou, K.A.; Kim, D.H. Biomechanical, Biochemical, and Histological Characterization of Canine Lumbar Facet Joint Cartilage. *Neurosurgery* **2010**, *66*, 722–727. [[CrossRef](#)] [[PubMed](#)]
79. Reddi, A.H. Cartilage morphogenetic proteins: Role in joint development, homeostasis, and regeneration. *Ann. Rheum. Dis.* **2003**, *62*, 73–78. [[CrossRef](#)]
80. Yang, Z.; Shi, Y.; Wei, X.; He, J.; Yang, S.; Dickson, G.; Tang, J.; Xiang, J.; Song, C.; Li, G. Fabrication and repair of cartilage defects with a novel acellular cartilage matrix scaffold. *Tissue Eng. Part C Methods* **2010**, *16*, 865–876. [[CrossRef](#)]
81. Nie, X.; Jin, Y.; Zhu, W.; He, P.; Peck, Y.; Wang, D. Decellularized tissue engineered hyaline cartilage graft for articular cartilage repair. *Biomaterials* **2020**, *235*, 119821. [[CrossRef](#)]
82. Shin, M.; Vacanti, J. Tissue engineering. *Emerg. Technol. Surg.* **2007**, *10*, 133–151.
83. Benders, K.E.M.; Boot, W.; Cokelaere, S.M.; Van Weeren, P.R.; Gawlitta, D.; Bergman, H.J.; Saris, D.B.F.; Dhert, W.J.A.; Malda, J. Multipotent Stromal Cells Outperform Chondrocytes on Cartilage-Derived Matrix Scaffolds. *Cartilage* **2014**, *5*, 221–230. [[CrossRef](#)]
84. Costa, A.; Naranjo, J.D.; Londono, R.; Badylak, S.F. Biologic scaffolds. *Cold Spring Harb. Perspect. Med.* **2017**, *7*, 1–24. [[CrossRef](#)] [[PubMed](#)]
85. Ruderman, N.; Chisholm, D.; Pi-Sunyer, X.; Schneider, S. The metabolically obese, normal-weight individual revisited. *Diabetes* **1998**, *47*, 699–713. [[CrossRef](#)] [[PubMed](#)]
86. Hemmrich, K.; von Heimburg, D. Biomaterials for adipose tissue engineering. *Expert Rev. Med. Devices* **2006**, *3*, 635–645. [[CrossRef](#)] [[PubMed](#)]
87. Girandon, L.; Kregar-Velikonja, N.; Božikov, K.; Barlič, A. In vitro models for adipose tissue engineering with adipose-derived stem cells using different scaffolds of natural origin. *Folia Biol.* **2011**, *57*, 47–56. [[PubMed](#)]
88. Onnely, E.D.; Riffin, M.G.; Utler, P.E.B. Breast Reconstruction with a Tissue Engineering and Regenerative Medicine Approach (Systematic Review). *Ann. Biomed. Eng.* **2020**, *48*, 9–25. [[CrossRef](#)]

89. Banyard, D.A.; Sarantopoulos, C.; Tassej, J.; Ziegler, M.; Chnari, E.; Evans, G.R.D.; Widgerow, A.D. Preparation, Characterization, and Clinical Implications of Human Decellularized Adipose Tissue Extracellular Matrix. In *Regenerative Medicine and Plastic Surgery*; Springer International Publishing: New York City, NY, USA, 2019; pp. 71–89.
90. Flynn, L.E. The use of decellularized adipose tissue to provide an inductive microenvironment for the adipogenic differentiation of human adipose-derived stem cells. *Biomaterials* **2010**, *31*, 4715–4724. [[CrossRef](#)]
91. Yu, C.; Kornmuller, A.; Brown, C.; Hoare, T.; Flynn, L.E. Decellularized adipose tissue microcarriers as a dynamic culture platform for human adipose-derived stem/stromal cell expansion. *Biomaterials* **2017**, *120*, 66–80. [[CrossRef](#)]
92. Yu, C.; Bianco, J.; Brown, C.; Fuetterer, L.; Watkins, J.F.; Samani, A.; Flynn, L.E. Porous decellularized adipose tissue foams for soft tissue regeneration. *Biomaterials* **2013**, *34*, 3290–3302. [[CrossRef](#)]
93. Song, M.; Liu, Y.; Hui, L. Preparation and characterization of acellular adipose tissue matrix using a combination of physical and chemical treatments. *Mol. Med. Rep.* **2018**, *17*, 138–146. [[CrossRef](#)]
94. Wang, L.; Johnson, J.A.; Zhang, Q.; Beahm, E.K. Combining decellularized human adipose tissue extracellular matrix and adipose-derived stem cells for adipose tissue engineering. *Acta Biomater.* **2013**, *9*, 8921–8931. [[CrossRef](#)]
95. Choi, Y.C.; Choi, J.S.; Kim, B.S.; Kim, J.D.; Yoon, H.I.; Cho, Y.W. Decellularized extracellular matrix derived from porcine adipose tissue as a xenogeneic biomaterial for tissue engineering. *Tissue Eng. Part C Methods* **2012**, *18*, 866–876. [[CrossRef](#)] [[PubMed](#)]
96. Gillies, A.R.; Lieber, R.L. Structure and function of the skeletal muscle extracellular matrix. *Muscle Nerve* **2011**, *44*, 318–331. [[CrossRef](#)]
97. Gefen, A.; van Nierop, B.; Bader, D.L.; Oomens, C.W. Strain-time cell-death threshold for skeletal muscle in a tissue-engineered model system for deep tissue injury. *J. Biomech.* **2008**, *41*, 2003–2012. [[CrossRef](#)] [[PubMed](#)]
98. Porzionato, A.; Sfriso, M.M.; Pontini, A.; Macchi, V.; Petrelli, L.; Pavan, P.G.; Natali, A.N.; Bassetto, F.; Vindigni, V.; De Caro, R. Decellularized human skeletal muscle as biologic scaffold for reconstructive surgery. *Int. J. Mol. Sci.* **2015**, *16*, 14808–14831. [[CrossRef](#)] [[PubMed](#)]
99. Zhang, J.; Qian, Z.; Turner, N.J.; Feng, S.; Yue, W.; Yang, H.; Zhang, L.; Wei, H.; Wang, Q.; Badylak, S.F. Perfusion-decellularized skeletal muscle as a three-dimensional scaffold with a vascular network template. *Biomaterials* **2016**, *89*, 114–126. [[CrossRef](#)] [[PubMed](#)]
100. Gillies, A.R.; Smith, L.R.; Lieber, R.L.; Varghese, S. Method for decellularizing skeletal muscle without detergents or proteolytic enzymes. *Tissue Eng. Part C Methods* **2011**, *17*, 383–389. [[CrossRef](#)]
101. Wilson, K.; Terlouw, A.; Roberts, K.; Wolchok, J.C.; Program, M.B. The Characterization of Decellularized Human Skeletal Muscle as a Blueprint for Mimetic Scaffolds. *J. Mater. Sci. Mater. Med.* **2016**, *27*, 1–29. [[CrossRef](#)]
102. Liu, Y.; Ramanath, H.S.; Wang, D.A. Tendon tissue engineering using scaffold enhancing strategies. *Trends Biotechnol.* **2008**, *26*, 201–209. [[CrossRef](#)]
103. Lockhart, M.; Wirrig, E.; Phelps, A.; Wessels, A. Extracellular Matrix and Heart Development. *Birth Defects Res. Part A Clin. Mol. Teratol.* **2011**, *91*, 535–550. [[CrossRef](#)]
104. Bayomy, A.F.; Bauer, M.; Qiu, Y.; Liao, R. Regeneration in heart disease—Is ECM the key? *Life Sci.* **2012**, *91*, 823–827. [[CrossRef](#)]
105. Eitan, Y.; Sarig, U.; Dahan, N.; Machluf, M. Acellular Cardiac Extracellular Matrix as a Scaffold for Tissue Engineering: In Vitro Cell Support, Remodeling, and Biocompatibility. *Tissue Eng. Part C Methods* **2010**, *16*. [[CrossRef](#)] [[PubMed](#)]
106. Prat-vidal, C.; Bayes-genis, A. Decellularized pericardial extracellular matrix: The preferred porous scaffold for regenerative medicine. *Xenotransplantation* **2020**, *27*, e12580. [[CrossRef](#)]
107. Di Meglio, F.; Nurzynska, D.; Romano, V.; Miraglia, R.; Belviso, I.; Sacco, A.M.; Barbato, V.; Di Gennaro, M.; Granato, G.; Maiello, C.; et al. Optimization of human myocardium decellularization method for the construction of implantable patches. *Tissue Eng.* **2017**, *23*, 525–539. [[CrossRef](#)] [[PubMed](#)]
108. Guyette, J.P.; Charest, J.M.; Mills, R.W.; Jank, B.J.; Moser, P.T.; Gilpin, S.E.; Gershlak, J.R.; Okamoto, T.; Gonzalez, G.; Milan, D.J.; et al. Bioengineering Human Myocardium on Native Extracellular Matrix. *Circ. Res.* **2015**, *118*, 56–72. [[CrossRef](#)]

109. Goldfracht, I.; Efraim, Y.; Shinnawi, R.; Kovalev, E.; Huber, I.; Gepstein, A.; Arbel, G.; Shaheen, N.; Tiburcy, M.; Zimmermann, W.H.; et al. Acta Biomaterialia Engineered heart tissue models from hiPSC-derived cardiomyocytes and cardiac ECM for disease modeling and drug testing applications. *Acta Biomater.* **2019**, *92*, 145–159. [[CrossRef](#)]
110. Efraim, Y.; Sarig, H.; Cohen, N.; Sarig, U.; de Berardinis, E.; Chaw, S. Acta Biomaterialia Biohybrid cardiac ECM-based hydrogels improve long term cardiac function post myocardial infarction. *Acta Biomater.* **2017**, *50*, 220–233. [[CrossRef](#)] [[PubMed](#)]
111. Wang, S.; Goecke, T.; Meixner, C.; Haverich, A.; Hilfiker, A.; Wolkers, W.F. Freeze-dried heart valve scaffolds. *Tissue Eng. Part C Methods* **2012**, *18*, 517–525. [[CrossRef](#)] [[PubMed](#)]
112. Haupt, J.; Lutter, G.; Gorb, S.N.; Simionescu, D.T.; Frank, D.; Seiler, J.; Paur, A.; Haben, I. Detergent-based decellularization strategy preserves macro- and microstructure of heart valves. *Interact. Cardio Vasc. Thorac. Surg.* **2018**, *26*, 230–236. [[CrossRef](#)] [[PubMed](#)]
113. Seo, Y.; Jung, Y.; Hyun, S. Biomaterialia Decellularized heart ECM hydrogel using supercritical carbon dioxide for improved angiogenesis. *Acta Biomater.* **2018**, *67*, 270–281. [[CrossRef](#)] [[PubMed](#)]
114. Cavinato, C.; Badel, P.; Krasny, W.; Avril, S.; Morin, C. Experimental Characterization of Adventitial Collagen Fiber Kinematics Using Second-Harmonic Generation Imaging Microscopy: Similarities and Differences Across Arteries, Species and Testing Conditions. *Tissue Eng. Biomater.* **2020**, *23*, 123–164. [[CrossRef](#)]
115. Suen, C.M.; Stewart, D.J.; Montroy, J.; Welsh, C.; Levac, B.; Wesch, N.; Zhai, A.; Fergusson, D.; McIntyre, L.; Lalu, M.M. Regenerative cell therapy for pulmonary arterial hypertension in animal models: A systematic review. *Stem Cell Res. Ther.* **2019**, *10*, 1–14. [[CrossRef](#)] [[PubMed](#)]
116. Homma, J.; Sekine, H.; Matsuura, K.; Kobayashi, E.; Shimizu, T. Mesenchymal Stem Cell Sheets Exert Antistenotic Effects in a Rat Arterial Injury Model. *Tissue Eng. Part A* **2018**, *24*, 1545–1553. [[CrossRef](#)] [[PubMed](#)]
117. Botham, C.M.; Bennett, W.L.; Cooke, J.P. Clinical trials of adult stem cell therapy for peripheral artery disease. *Methodist Debaquey Cardiovasc. J.* **2013**, *9*, 201–205. [[CrossRef](#)]
118. Raval, Z.; Losordo, D.W. Cell therapy of peripheral arterial disease: From experimental findings to clinical trials. *Circ. Res.* **2013**, *112*, 1288–1302. [[CrossRef](#)] [[PubMed](#)]
119. Iwasaki, K.; Kojima, K.; Kodama, S.; Paz, A.C.; Chambers, M.; Umezu, M.; Vacanti, C.A. Bioengineered three-layered robust and elastic artery using hemodynamically-equivalent pulsatile bioreactor. *Circulation* **2008**, *118*, 52–57. [[CrossRef](#)]
120. Cai, Z.; Gu, Y.; Cheng, J.; Li, J.; Xu, Z.; Xing, Y.; Wang, C.; Wang, Z. Decellularization, cross-linking and heparin immobilization of porcine carotid arteries for tissue engineering vascular grafts. *Cell Tissue Bank.* **2019**, *20*, 569–578. [[CrossRef](#)]
121. Schneider, K.H.; Enayati, M.; Grasl, C.; Walter, I.; Budinsky, L.; Zebic, G.; Kaun, C.; Wagner, A.; Kratochwill, K.; Redl, H.; et al. Acellular vascular matrix grafts from human placenta chorion: Impact of ECM preservation on graft characteristics, protein composition and in vivo performance. *Biomaterials* **2018**, *177*, 14–26. [[CrossRef](#)]
122. Hany, K.; Park, K.; Yu, L.; Song, S.; Woo, H.; Kwak, H. Vascular reconstruction: A major challenge in developing a functional whole solid organ graft from decellularized organs. *Acta Biomater.* **2020**, *103*, 68–80. [[CrossRef](#)]
123. Kajbafzadeh, A.M.; Khorramirouz, R.; Kameli, S.M.; Hashemi, J.; Bagheri, A. Decellularization of Human Internal Mammary Artery: Biomechanical Properties and Histopathological Evaluation. *Biores. Open Access* **2017**, *6*, 74–84. [[CrossRef](#)]
124. Mayorca-Guiliani, A.E.; Willacy, O.; Madsen, C.D.; Rafeeva, M.; Elisabeth Heumüller, S.; Bock, F.; Sengle, G.; Koch, M.; Imhof, T.; Zaucke, F.; et al. Decellularization and antibody staining of mouse tissues to map native extracellular matrix structures in 3D. *Nat. Protoc.* **2019**, *14*, 3395–3425. [[CrossRef](#)]
125. Gil-Ramírez, A.; Rosmark, O.; Spégel, P.; Swärd, K.; Westergren-Thorsson, G.; Larsson-Callerfelt, A.K.; Rodríguez-Meizoso, I. Pressurized carbon dioxide as a potential tool for decellularization of pulmonary arteries for transplant purposes. *Sci. Rep.* **2020**, *10*, 1–12. [[CrossRef](#)] [[PubMed](#)]
126. Tracy, L.E.; Minasian, R.A.; Caterson, E.J. Extracellular Matrix and Dermal Fibroblast Function in the Healing Wound. *Adv. Wound Care* **2016**, *5*, 119–136. [[CrossRef](#)]
127. Jevtić, M.; Löwa, A.; Nováčková, A.; Kováčik, A.; Kaessmeyer, S.; Erdmann, G.; Vávrová, K.; Hedtrich, S. Impact of intercellular crosstalk between epidermal keratinocytes and dermal fibroblasts on skin homeostasis. *Biochim. Biophys. Acta Mol. Cell Res.* **2020**, *1867*, 118722. [[CrossRef](#)] [[PubMed](#)]

128. Pouliot, R.; Larouche, D.; Auger, F.A.; Juhasz, J.; Xu, W.; Li, H.; Germain, L. Reconstructed human skin produced in vitro and grafted on athymic mice. *Transplantation* **2002**, *73*, 1751–1757. [[CrossRef](#)] [[PubMed](#)]
129. Zhang, Y.; Iwata, T.; Nam, K.; Kimura, T.; Wu, P.; Nakamura, N.; Hashimoto, Y.; Kishida, A. Water absorption by decellularized dermis. *Heliyon* **2018**, *4*, e00600. [[CrossRef](#)] [[PubMed](#)]
130. Wolf, M.T.; Daly, K.A.; Brennan-Pierce, E.P.; Johnson, S.A.; Carruthers, C.A.; D'Amore, A.; Nagarkar, S.P.; Velankar, S.S.; Badylak, S.F. A hydrogel derived from decellularized dermal extracellular matrix. *Biomaterials* **2012**, *33*, 7028–7038. [[CrossRef](#)] [[PubMed](#)]
131. Lau, C.S.; Hassanbhai, A.; Wen, F.; Wang, D.; Chanchareonsook, N.; Goh, B.T.; Yu, N.; Teoh, S.H. Evaluation of decellularized tilapia skin as a tissue engineering scaffold. *J. Tissue Eng. Regen. Med.* **2019**, *13*, 1779–1791. [[CrossRef](#)]
132. Farrokhi, A.; Pakyari, M.; Nabai, L.; Pourghadiri, A.; Hartwell, R.; Jalili, R.; Ghahary, A. Evaluation of Detergent-Free and Detergent-Based Methods for Decellularization of Murine Skin. *Tissue Eng. Part A* **2018**, *24*, 955–967. [[CrossRef](#)]
133. Wallis, J.M.; Borg, Z.D.; Daly, A.B.; Deng, B.; Ballif, B.A.; Allen, G.B.; Jaworski, D.M.; Weiss, D.J. Comparative assessment of detergent-based protocols for mouse lung de-cellularization and re-cellularization. *Tissue Eng. Part C Methods* **2012**, *18*, 420–432. [[CrossRef](#)]
134. Hung, S.H.; Su, C.H.; Lin, S.E.; Tseng, H. Preliminary experiences in trachea scaffold tissue engineering with segmental organ decellularization. *Laryngoscope* **2016**, *126*, 2520–2527. [[CrossRef](#)]
135. Cozad, M.J.; Bachman, S.L.; Grant, S.A. Assessment of decellularized porcine diaphragm conjugated with gold nanomaterials as a tissue scaffold for wound healing. *J. Biomed. Mater. Res. Part A* **2011**, *99*, 426–434. [[CrossRef](#)] [[PubMed](#)]
136. Zang, M.; Zhang, Q.; Chang, E.I.; Mathur, A.B.; Yu, P. Decellularized tracheal matrix scaffold for tracheal tissue engineering: In vivo host response. *Plast. Reconstr. Surg.* **2013**, *132*, 549–559. [[CrossRef](#)]
137. Philipp, T.; Mgerliuclacuk, E.; Gillian, R.; Jonathan, M. Creation of Laryngeal Grafts from Primary Human Cells and Decellularized Laryngeal Scaffolds. *Tissue Eng.* **2019**, *26*, 543–555. [[CrossRef](#)]
138. Zang, M.; Zhang, Q.; Chang, E.I.; Mathur, A.B.; Yu, P. Decellularized tracheal matrix scaffold for tissue engineering. *Plast. Reconstr. Surg.* **2012**, *130*, 532–540. [[CrossRef](#)]
139. Remlinger, N.T.; Czajka, C.A.; Juhas, M.E.; Vorp, D.A.; Stolz, D.B.; Badylak, S.F.; Gilbert, S.; Gilbert, T.W. Hydrated xenogeneic decellularized tracheal matrix as a scaffold for tracheal reconstruction. *Biomaterials* **2010**, *31*, 3520–3526. [[CrossRef](#)]
140. Weiss, D.J. Concise review: Current status of stem cells and regenerative medicine in lung biology and diseases. *Stem Cells* **2014**, *32*, 16–25. [[CrossRef](#)] [[PubMed](#)]
141. O'Neill, J.D.; Anfang, R.; Anandappa, A.; Costa, J.; Javidfar, J.; Wobma, H.M.; Singh, G.; Freytes, D.O.; Bacchetta, M.D.; Sonett, J.R.; et al. Decellularization of human and porcine lung tissues for pulmonary tissue engineering. *Ann. Thorac. Surg.* **2013**, *96*, 1046–1056. [[CrossRef](#)] [[PubMed](#)]
142. Gilpin, S.E.; Guyette, J.P.; Gonzalez, G.; Ren, X.; Asara, J.M.; Mathisen, D.J.; Vacanti, J.P.; Ott, H.C. Perfusion decellularization of human and porcine lungs: Bringing the matrix to clinical scale. *J. Hear. Lung Transplant.* **2014**, *33*, 298–308. [[CrossRef](#)]
143. Giraldo-Gomez, D.M.; Leon-Mancilla, B.; Del Prado-Audelo, M.L.; Sotres-Vega, A.; Villalba-Caloca, J. Trypsin as enhancement in cyclical tracheal decellularization: Morphological and biophysical characterization. *Mater. Sci. Eng. C* **2016**, *59*, 930–937. [[CrossRef](#)]
144. Ershadi, R.; Rahim, M.; Jahany, S. Transplantation of the decellularized tracheal allograft in animal model (rabbit). *Asian J. Surg.* **2018**, *41*, 328–332. [[CrossRef](#)]
145. Orlando, G.; García-Arrarás, J.E.; Soker, T.; Booth, C.; Sanders, B.; Ross, C.L.; De Coppi, P.; Farney, A.C.; Rogers, J.; Stratta, R.J. Regeneration and bioengineering of the gastrointestinal tract: Current status and future perspectives. *Dig. Liver Dis.* **2012**, *44*, 714–720. [[CrossRef](#)] [[PubMed](#)]
146. Hussey, G.S.; Cramer, M.C.; Badylak, S.F. Extracellular Matrix Bioscaffolds for Building Gastrointestinal Tissue. *Cmgh* **2018**, *5*, 1–13. [[CrossRef](#)] [[PubMed](#)]
147. Hussey, G.S.; Keane, T.J.; Badylak, S.F. The extracellular matrix of the gastrointestinal tract: A regenerative medicine platform. *Nat. Rev. Gastroenterol. Hepatol.* **2017**, *14*, 540–552. [[CrossRef](#)] [[PubMed](#)]
148. Urbani, L.; Camilli, C.; Phylactopoulos, D.E.; Crowley, C.; Natarajan, D.; Scottoni, F.; Maghsoudlou, P.; McCann, C.J.; Pellegata, A.F.; Urciuolo, A.; et al. Multi-stage bioengineering of a layered oesophagus with in vitro expanded muscle and epithelial adult progenitors. *Nat. Commun.* **2018**, *9*, 4286. [[CrossRef](#)]

149. Meran, L.; Baulies, A.; Li, V.S.W. Intestinal Stem Cell Niche: The Extracellular Matrix and Cellular Components. *Stem Cells Int.* **2017**, *2017*, 7970385. [[CrossRef](#)]
150. Wang, Y.; Kim, R.; Hinman, S.S.; Zwarycz, B.; Magness, S.T.; Allbritton, N.L. Bioengineered Systems and Designer Matrices That Recapitulate the Intestinal Stem Cell Niche. *Cell. Mol. Gastroenterol. Hepatol.* **2018**, *5*, 440–453. [[CrossRef](#)]
151. Maghsoudlou, P.; Totonelli, G.; Loukogeorgakis, S.P.; Eaton, S.; De Coppi, P. A decellularization methodology for the production of a natural acellular intestinal matrix. *J. Vis. Exp.* **2013**. [[CrossRef](#)]
152. Kajbafzadeh, A.M.; Khorramirouz, R.; Masoumi, A.; Keihani, S.; Nabavizadeh, B. Decellularized human fetal intestine as a bioscaffold for regeneration of the rabbit bladder submucosa. *J. Pediatr. Surg.* **2018**, *53*, 1781–1788. [[CrossRef](#)]
153. Ashton, G.H.; Morton, J.P.; Myant, K.; Phesse, T.J.; Ridgway, R.A.; Marsh, V.; Wilkins, J.A.; Athineos, D.; Muncan, V.; Kemp, R.; et al. Focal Adhesion Kinase is required for intestinal regeneration and tumorigenesis downstream of Wnt/c-Myc signaling. *Dev. Cell* **2010**, *19*, 259–269. [[CrossRef](#)]
154. Giobbe, G.G.; Crowley, C.; Luni, C.; Campinoti, S.; Khedr, M.; Kretzschmar, K.; De Santis, M.M.; Zambaiti, E.; Michielin, F.; Meran, L.; et al. Extracellular matrix hydrogel derived from decellularized tissues enables endodermal organoid culture. *Nat. Commun.* **2019**, *10*, 5658. [[CrossRef](#)]
155. Badylak, S.F.; Lantz, G.C.; Coffey, A.; Geddes, L.A. Small intestinal submucosa as a large diameter vascular graft in the dog. *J. Surg. Res.* **1989**, *47*, 74–80. [[CrossRef](#)]
156. Daley, M.C.; Fenn, S.L.; Iii, L.D.B. *Cardiac Extracellular Matrix*; Springer International Publishing: New York City, NY, USA, 2018; Volume 1098, ISBN 978-3-319-97420-0.
157. Cobb, M.A.; Badylak, S.F.; Janas, W.; Simmons-Byrd, A.; Boop, F.A. Porcine small intestinal submucosa as a dural substitute. *Surg. Neurol.* **1999**, *51*, 99–104. [[CrossRef](#)]
158. Clarke, K.M.; Lantz, G.C.; Salisbury, S.K.; Badylak, S.F.; Hiles, M.C.; Voytik, S.L. Intestine submucosa and polypropylene mesh for abdominal wall repair in dogs. *J. Surg. Res.* **1996**, *60*, 107–114. [[CrossRef](#)] [[PubMed](#)]
159. Wallis, M.C.; Yeager, H.; Cartwright, L.; Shou, Z.; Radisic, M.; Haig, J.; Suoub, M.; Antoon, R.; Farhat, W.A. Feasibility study of a novel urinary bladder bioreactor. *Tissue Eng. Part A* **2008**, *14*, 339–348. [[CrossRef](#)]
160. Chen, M.K.; Badylak, S.F. Small bowel tissue engineering using small intestinal submucosa as a scaffold. *J. Surg. Res.* **2001**, *99*, 352–358. [[CrossRef](#)]
161. Oliveira, A.C.; Garzón, I.; Ionescu, A.M.; Carriel, V.; de la Cruz Cardona, J.; González-Andrades, M.; del Mar Perez, M.; Alaminos, M.; Campos, A. Evaluation of Small Intestine Grafts Decellularization Methods for Corneal Tissue Engineering. *PLoS ONE* **2013**, *8*, e66538. [[CrossRef](#)]
162. Syed, O.; Walters, N.J.; Day, R.M.; Kim, H.W.; Knowles, J.C. Evaluation of decellularization protocols for production of tubular small intestine submucosa scaffolds for use in oesophageal tissue engineering. *Acta Biomater.* **2014**, *10*, 5043–5054. [[CrossRef](#)]
163. Hodde, J.P.; Badylak, S.F.; Donald Shelbourne, K. The effect of range of motion on remodeling of small intestinal submucosa (SIS) when used as an achilles tendon repair material in the rabbit. *Tissue Eng.* **1997**, *3*, 27–37. [[CrossRef](#)]
164. Cook, J.L.; Tomlinson, J.L.; Arnoczky, S.P.; Fox, D.B.; Cook, C.R.; Kreeger, J.M. Kinetic study of the replacement of porcine small intestinal submucosa grafts and the regeneration of meniscal-like tissue in large avascular meniscal defects in dogs. *Tissue Eng.* **2001**, *7*, 321–334. [[CrossRef](#)]
165. Prevel, C.D.; Eppley, B.L.; Summerlin, D.J.; Sidner, R.; Jackson, J.R.; McCarty, M.; Badylak, S.F. Small intestinal submucosa: Utilization as a wound dressing in full-thickness rodent wounds. *Ann. Plast. Surg.* **1995**, *35*, 381–388. [[CrossRef](#)]
166. Moore, D.C.; Pedrozo, H.A.; Crisco, J.J.; Ehrlich, M.G. Preformed grafts of porcine small intestine submucosa (SIS) for bridging segmental bone defects. *J. Biomed. Mater. Res. Part A* **2004**, *69*, 259–266. [[CrossRef](#)] [[PubMed](#)]
167. Baptista, P.M.; Vyas, D.; Moran, E.; Wang, Z.; Soker, S. Human liver bioengineering using a whole liver decellularized bioscaffold. *Methods Mol. Biol.* **2013**, *1001*, 289–298. [[CrossRef](#)] [[PubMed](#)]
168. Mazza, G.; Rombouts, K.; Rennie Hall, A.; Urbani, L.; Vinh Luong, T.; Al-Akkad, W.; Longato, L.; Brown, D.; Maghsoudlou, P.; Dhillon, A.P.; et al. Decellularized human liver as a natural 3D-scaffold for liver bioengineering and transplantation. *Sci. Rep.* **2015**, *5*, 1–15. [[CrossRef](#)] [[PubMed](#)]

169. Mazza, G.; Al-Akkad, W.; Telese, A.; Longato, L.; Urbani, L.; Robinson, B.; Hall, A.; Kong, K.; Frenguelli, L.; Marrone, G.; et al. Rapid production of human liver scaffolds for functional tissue engineering by high shear stress oscillation-decellularization. *Sci. Rep.* **2017**, *7*, 1–14. [[CrossRef](#)]
170. Gonzalez-Perez, F.; Udina, E.; Navarro, X. *Extracellular Matrix Components in Peripheral Nerve Regeneration*, 1st ed.; Elsevier Inc.: Amsterdam, The Netherlands, 2013; Volume 108, ISBN 9780124104990.
171. Terenghi, G. Peripheral nerve injury and regeneration. *Histol. Histopathol.* **1995**, *10*, 709–718. [[PubMed](#)]
172. Baiguera, S.; Del Gaudio, C.; Lucatelli, E.; Kuevda, E.; Boieri, M.; Mazzanti, B.; Bianco, A.; Macchiarini, P. Electrospun gelatin scaffolds incorporating rat decellularized brain extracellular matrix for neural tissue engineering. *Biomaterials* **2014**, *35*, 1205–1214. [[CrossRef](#)]
173. Ghasemi-Mobarakeh, L.; Prabhakaran, M.P.; Morshed, M.; Nasr-Esfahani, M.H.; Baharvand, H.; Kiani, S.; Al-Deyab, S.S.; Ramakrishna, S. Application of conductive polymers, scaffolds and electrical stimulation for nerve tissue engineering. *J. Tissue Eng. Regen. Med.* **2011**, *5*, e17–e35. [[CrossRef](#)]
174. Heikkinen, A.; Pihlajaniemi, T.; Faissner, A.; Yuzaki, M. Neural ECM and Synaptogenesis. In *Progress in Brain Research*; Elsevier B.V.: Amsterdam, The Netherlands, 2014; Volume 214, pp. 29–51.
175. Arslan, Y.E.; Efe, B.; Sezgin Arslan, T. A novel method for constructing an acellular 3D biomatrix from bovine spinal cord for neural tissue engineering applications. *Biotechnol. Prog.* **2019**, *35*, e2814. [[CrossRef](#)]
176. DelMonte, D.W.; Kim, T. Anatomy and physiology of the cornea. *J. Cataract Refract. Surg.* **2011**, *37*, 588–598. [[CrossRef](#)]
177. Eghrari, A.O.; Riazuddin, S.A.; Gottsch, J.D. *Overview of the Cornea: Structure, Function, and Development*, 1st ed.; Elsevier Inc.: Baltimore, MD, USA, 2015; Volume 134, ISBN 9780128010594.
178. Ghezzi, C.E.; Rnjak-Kovacina, J.; Kaplan, D.L. Corneal Tissue Engineering: Recent Advances and Future Perspectives. *Tissue Eng. Part B Rev.* **2015**, *21*, 278–287. [[CrossRef](#)]
179. Matthyssen, S.; Van den Bogerd, B.; Dhuhghaill, S.N.; Koppen, C.; Zakaria, N. Corneal regeneration: A review of stromal replacements. *Acta Biomater.* **2018**, *69*, 31–41. [[CrossRef](#)] [[PubMed](#)]
180. Mahdavi, S.S.; Abdekhodaie, M.J. Bioengineering Approaches for Corneal Regenerative Medicine. *Tissue Eng. Regen. Med.* **2020**. [[CrossRef](#)] [[PubMed](#)]
181. Chen, Z.; You, J.; Liu, X.; Cooper, S.; Hodge, C.; Sutton, G.; Crook, J.M.; Wallace, G.G. Biomaterials for corneal bioengineering. *Biomed. Mater.* **2018**, *13*, 32002. [[CrossRef](#)]
182. Zhang, B.; Xue, Q.; Li, J.; Ma, L.; Yao, Y.; Ye, H.; Cui, Z. 3D bioprinting for artificial cornea: Challenges and perspectives. *Med. Eng. Phys.* **2019**, *71*, 68–78. [[CrossRef](#)]
183. Wilson, S.L.; Sidney, L.E.; Dunphy, S.E.; Dua, H.S.; Hopkinson, A. Corneal Decellularization: A Method of Recycling Unsuitable Donor Tissue for Clinical Translation? *Curr. Eye Res.* **2016**, *41*, 769–782. [[CrossRef](#)] [[PubMed](#)]
184. Fernández-pérez, J.; Ahearne, M. The impact of decellularization methods on extracellular matrix derived hydrogels. *Nature* **2019**, *9*, 1–12. [[CrossRef](#)]
185. Alio del Barrio, J.L.; Chiesa, M.; Garagorri, N.; Garcia-Urquia, N.; Fernandez-Delgado, J.; Bataille, L.; Rodriguez, A.; Arnalich-Montiel, F.; Zarnowski, T.; Álvarez de Toledo, J.P.; et al. Acellular human corneal matrix sheets seeded with human adipose-derived mesenchymal stem cells integrate functionally in an experimental animal model. *Exp. Eye Res.* **2015**, *132*, 91–100. [[CrossRef](#)]
186. Liu, J.; Li, Z.; Li, J.; Liu, Z. Application of benzonase in preparation of decellularized lamellar porcine corneal stroma for lamellar keratoplasty. *J. Biomed. Mater. Res. Part A* **2019**, *107*, 2547–2555. [[CrossRef](#)]
187. Piccinini, E.; Bonfanti, P. Disassembling and Reaggregating the Thymus: The Pros and Cons of Current Assays. In *Immunological Tolerance*; Humana Press: New York, NY, USA, 2019; Volume 1899, ISBN 9781493989386.
188. Tajima, A.; Pradhan, I.; Trucco, M.; Fan, Y. Restoration of Thymus Function with Bioengineered Thymus Organoids. *Curr. Stem Cell Rep.* **2016**, *2*, 128–139. [[CrossRef](#)]
189. Tajima, A.; Pradhan, I.; Geng, X.; Trucco, M.; Fan, Y. Construction of Thymus Organoids from Decellularized Thymus Scaffolds. *Methods Mol. Biol.* **2019**, *1576*, 33–42.
190. Fan, Y.; Tajima, A.; Goh, S.K.; Geng, X.; Gualtierotti, G.; Grupillo, M.; Coppola, A.; Bertera, S.; Rudert, W.A.; Banerjee, I.; et al. Bioengineering Thymus Organoids to Restore Thymic Function and Induce Donor-Specific Immune Tolerance to Allografts. *Mol. Ther.* **2015**, *23*, 1262–1277. [[CrossRef](#)] [[PubMed](#)]
191. Badylak, S.F.; Freytes, D.O.; Gilbert, T.W. Extracellular matrix as a biological scaffold material: Structure and function. *Acta Biomater.* **2009**, *5*, 1–13. [[CrossRef](#)] [[PubMed](#)]

192. Brown, B.N.; Badylak, S.F. Extracellular matrix as an inductive scaffold for functional tissue reconstruction. *Transl. Res.* **2014**, *163*, 268–285. [[CrossRef](#)] [[PubMed](#)]
193. Folli, S.; Curcio, A.; Melandri, D.; Bondioli, E.; Rocco, N.; Catanuto, G.; Falcini, F.; Purpura, V.; Mingozzi, M.; Buggi, F.; et al. A New Human-Derived Acellular Dermal Matrix for Breast Reconstruction Available for the European Market: Preliminary Results. *Aesthetic Plast. Surg.* **2018**, *42*, 434–441. [[CrossRef](#)]
194. Neumann, A.; Sarikouch, S.; Breymann, T.; Cebotari, S.; Boethig, D.; Horke, A.; Beerbaum, P.; Westhoff-Bleck, M.; Bertram, H.; Ono, M.; et al. Early systemic cellular immune response in children and young adults receiving decellularized fresh allografts for pulmonary valve replacement. *Tissue Eng. Part A* **2014**, *20*, 1003–1011. [[CrossRef](#)]
195. Elkins, R.C.; Dawson, P.E.; Goldstein, S.; Walsh, S.P.; Black, K.S. Decellularized human valve allografts. *Ann. Thorac. Surg.* **2001**, *71*, S428–S432. [[CrossRef](#)]
196. Cheng, A.; Saint-Cyr, M. Comparison of Different ADM Materials in Breast Surgery. *Clin. Plast. Surg.* **2012**, *39*, 167–175. [[CrossRef](#)]
197. Zenn, M.; Venturi, M.; Pittman, T.; Spear, S.; Gurtner, G.; Robb, G.; Mesbahi, A.; Dayan, J. Optimizing Outcomes of Postmastectomy Breast Reconstruction with Acellular Dermal Matrix: A Review of Recent Clinical Data. *Eplasty* **2017**, *17*, e18. [[PubMed](#)]
198. Brooke, S.; Mesa, J.; Uluer, M.; Michelotti, B.; Moyer, K.; Neves, R.I.; MacKay, D.; Potochny, J. Complications in tissue expander breast reconstruction: A comparison of AlloDerm, DermaMatrix, and FlexHD acellular inferior pole dermal slings. *Ann. Plast. Surg.* **2012**, *69*, 347–349. [[CrossRef](#)]
199. Tal, H.; Moses, O.; Zohar, R.; Meir, H.; Nemcovsky, C. Root Coverage of Advanced Gingival Recession: A Comparative Study Between Acellular Dermal Matrix Allograft and Subepithelial Connective Tissue Grafts. *J. Periodontol.* **2002**, *73*, 1405–1411. [[CrossRef](#)]
200. Bruyneel, A.A.N.; Carr, C.A. Ambiguity in the Presentation of Decellularized Tissue Composition: The Need for Standardized Approaches. *Artif. Organs* **2017**, *41*, 778–784. [[CrossRef](#)] [[PubMed](#)]
201. Hoshiba, T.; Yamaoka, T. (Eds.) *Decellularized Extracellular Matrix: Characterization, Fabrication and Applications*; Royal Society of Chemistry: London, UK, 2019.



© 2020 by the authors. Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (<http://creativecommons.org/licenses/by/4.0/>).